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ABSTRACT OF THE DISSERTATION
A MULTIMODAL NEUROIMAGING APPROACH FOR CLASSIFICATION AND
PREDICTION OF ALZHEIMER’S DISEASE USING MACHINE LEARNING
by
Parisa Forouzannezhad
Florida International University, 2020
Miami, Florida
Professor Malek Adjouadi, Major Professor
Alzheimer’s disease (AD) is one of the most common neurodegenerative disorders among
the elderly population. It is progressive, irreversible in nature and is considered the
main cause of dementia. AD has become a world health problem affecting developed
and developing nations alike, with the number of diagnosed AD patients increasing rather
dramatically as both the life span of humans and the earth’s population continue to increase.
Therefore, AD diagnosis in its earliest manifestations, preferably at the presymptomatic
stage is critical for the timely planning of treatment and therapeutic interventions.
We introduce new machine learning algorithms to detect and predict the Alzheimer’s
disease in the early phase to include the presymptomatic stage where no manifestation of
cognitive decline is yet apparent. An investigation is carried out in search of optimal feature selection methods on different machine learning platforms with the intent to address
the challenging classification and regression analysis. This research endeavor introduces
three machine learning platforms that are based on (1) deep neural network, (2) support
vector machine (SVM), and (3) Gaussian-based model classifiers all optimized in order to
delineate the different stages of the disease as well as a regression framework to predict
future cognitive scores as means to gauge disease progression, which could play an important role in pre- and post-treatment evaluations. The input data to these machine learning
architectures included magnetic resonance imaging (MRI), positron emission tomogra-
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phy (PET), the metabolic fluorodeoxyglucose (FDG)-PET, cognitive scores, cerebrospinal
fluid (CSF), and the apolipoprotein E4 (APOE4) gene. An investigation is carried out
on the transition phases of AD through regression analysis by predicting cognitive tests
including Alzheimer’s disease assessment scale cognitive subscale (ADAS-Cog), Minimental state examination (MMSE), and Rey’s auditory verbal learning (RAVLT) that have
been designed and used as important criteria to evaluate cognitive status of AD patients.
We formulated the prediction of disease progression as a multimodal multitask regression
problem across six time points in a 4-year longitudinal study.
Major findings of this work reveal that for binary classification, the highest accuracy of
84% for delineating the challenging group of early mild cognitively impaired individuals
(EMCI) from the cognitively normal (CN) group is obtained. With multiclass classification
using deep neural network methodology, especially when early and late MCI (EMCI and
LMCI) groups are included, the accuracy does not exceed 70%, which clearly explains
the many nuances in the transition phases of the disease, especially in the early stages.
Moreover, the episodic tests like RVALT as used in this study were shown to be effective
for selecting the at-risk groups. MRI morphometry was found to be the most sensitive
biomarker to predict disease conversion and observed that parietal and prefrontal cortices
are also associated with episodic memory in addition to the temporal lobe. Although
adding the modalities of FDG-PET, CSF, and APOE allele gene improved the prediction
error significantly at 4 time points, multimodal neuroimaging does not statistically enhance
the prediction performance at some time points due to the inherent challenge of missing
data. It is clear that for longitudinal studies of such duration (4-year), beyond the variability
and interrelatedness of features, the missing data challenge remains the most difficult to
overcome.
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CHAPTER 1
INTRODUCTION
Alzheimer’s disease (AD) is one of the most common neurodegenerative disorders
among the elderly population. It is progressive, irreversible in nature and is considered
the main cause of dementia. Therefore, AD diagnosis in its earliest manifestations is
critical for the timely planning of treatment of this healthcare challenge. AD has become
a world health problem affecting developed and developing nations alike, and the number
of diagnosed AD patients is, unfortunately, increasing rather dramatically as both the life
span of humans and the earth’s population continue to increase. According to the 2018
report by the Alzheimer’s Association, 5.7 million Americans are living with Alzheimer’s
and by 2050 this number may reach 13.8 million [1].

Numerous studies over the recent years have confirmed that AD can be diagnosed by
clinical procedures in 90 percent of cases or higher; however, by the time that the AD
stage is diagnosed in patients, they might already lost a substantial part of their mental
function, and given the irreversible nature of the disease, the chance for early intervention
and the potential for slowing its progression become futile. Current studies confirmed that
10-15% of patients with amnestic mild cognitive impairment (MCI) progress to AD per
year [2]. However, in the early stages of the disease, the chance of slowing its progression is significantly higher. Several medications are approved by the US Food and Drug
Administration (FDA) to delay the onset of symptoms and slow down the progression of
dementia at its earliest prodromal phase; however, there is no absolute treatment for AD at
this time. Thus the potential for early curative or therapeutic intervention provides added
credence and significance to the accurate diagnosis of the early mild cognitive impairment
(EMCI) as an early stage in the prognosis of AD.

1

Diagnosis of AD is mostly based on the clinical history and some neuropsychological tests such as Mini-mental state examination (MMSE) and clinical dementia rating
(CDR). However, to understand brain pathology, modern imaging techniques, such as
magnetic resonance imaging (MRI) [3, 4], positron emission tomography (PET) [5–8],
and functional magnetic resonance imaging (fMRI) [9–12] used as complementary imaging modalities to explore the functional and metabolic interactions among the different
brain regions. Moreover, researchers use other biomarkers such as apolipoprotein (APOE)
genotype [13, 14], age, sex, and clinical and cognitive test scores [15, 16]. These neuroimaging techniques are non-invasive and provide valuable information for both clinical
and research purposes. In addition, multimodal neuroimaging uses the combination of
biomarkers to classify and predict AD and its different conversion phases [17–21] which
is a great platform for consolidating different measures that allows us to understand the
causality of AD and its different prodromal stages.

However, the high dimensionality of these neuroimaging datasets compounded with
the low number of multimodal neuroimaging samples available makes the analysis of these
types of data quite challenging. Patterns of neuronal cell death, at least in the early stages
of the disease, may not necessarily reflect the anatomical or functional abnormalities in the
different regions of the brain. Therefore, the analysis should not only carefully scrutinize
the different brain regions, with added focus on regions that are known to be disease
prone but also look at all potential biomarkers that are best suited to be combined in an
optimal fashion to detect these subtle changes. In order to overcome such a problem,
machine learning techniques were introduced to analyze medical images data [17, 22–25].
Machine learning algorithms try to find a low dimensional representation of the data which
is embedded in high dimensional space. These algorithms using discriminative features
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as MCI or AD biomarkers provide powerful models for computer-aided diagnosis for
Alzheimer’s [26, 27].

Recently, several machine learning techniques have been proposed for the detection
of AD and its prodromal stages; among them which are viewed as the most accurate and
most applicable approaches are artificial neural network (ANN), support vector machine
(SVM), and Bayesian network (BN). SVM is one of the most popular supervised machine learning models with associated learning algorithms to analyze the data applied for
classification [28–32]. Bayesian prediction and classification models are another type of
machine learning based on the Bayes theorem with the assumption of strong independence
among the classification features [33–36]. Deep neural networks and deep learning approach are able to analyze the high dimensional data such as MRI which has been widely
used in recent decades [17, 37–43].

SVM remains the most popular supervised machine learning model with associated
learning algorithms to analyze the data applied for classification. Through a set of training
examples, the SVM algorithm makes a model that is capable of assigning new test data
to one of the predefined classes. Cui et al. used anatomical atrophy features extracted
from MRI and anisotropy values extracted from diffusion images achieved an accuracy
of 71.09% for CN vs. MCI classification by applying an SVM-based method [44]. Suk
et al. introduced a deep learning multi-kernel SVM for classification of AD and MCI
by combining MRI and PET imaging [40]. In their approach, a set of autoencoders was
trained for each imaging modality; then, the obtained high-level features were applied to
the multi-kernel SVM for the classification. They obtained 90.7% accuracy for CN vs.
MCI and 98.8% for CN vs. AD classification using semi-supervised learning. Furthermore, different techniques based on DNN have been proposed to detect AD with a focus
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placed on the MCI group. Liu et al. introduced a new DNN using PET and MRI data
and have reported the accuracy of 82.1% for MCI detection from CN group [17]. Ortiz
et al. on the other hand introduced a deep belief neural network binary classification and
achieved 83% accuracy for the CN vs. MCI converter groups and 90% accuracy for the
CN vs. AD groups [45].

Bayesian prediction and classification models are another type of machine learning
based on the Bayes theorem with the assumption of strong independence among the classification features. Using such prediction methods, Plant et al. achieved 75% prediction
accuracy of the MCI to AD conversion using a combination of voting feature intervals,
SVM, and Bayesian model statistics [36]. Through this combination of the Bayesian-based
model and the feature selection process, they obtained an accuracy of 92% in the classification of AD and CN groups and 85.71% in the classification of CN and MCI groups. Some
other studies used Gaussian analysis which is based on Bayesian classification to perform
classification of MCI and AD [46, 47]. Fang et al. introduced Gaussian discriminative
analysis (GDA) for early detection of AD and achieved 87.43% accuracy of MCI and AD,
94.1% accuracy of CN and MCI, and 96.92% accuracy of CN and AD classifications using
MRI data [46]. In another study by Challis et al., the Bayesian Gaussian process-linear
regression model is applied on fMRI data and they report a classification accuracy of 75%
for the detection of amnestic MCI from CN and a 97% classification accuracy of aMCI
from AD group [47].

Several investigations are reported on the specific diagnosis of MCI, and high classification accuracy of the CN control group from the MCI group. Although such approaches
are commendable and have their own merit in shedding light on the progression of the
disease, the research community understands that for a disease like AD, the disease may
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have started for over a decade prior to any noticeable physical symptoms [48–51]. The
complexity of this challenge in delineating the MCI group from the CN group is reflected
in the type of classification results, often not exceeding the lower end of the 80% range, that
several studies have endeavored to resolve. These attempts, regardless of the multimodal
imaging approach and the integration of the different biomarkers along with the use of
neuropsychological test scores not initially used at baseline could not discover any new
measures that could potentially increase these classification results.

It is thus imperative to include the EMCI group in any prediction or classification study
that is bound to assess the different progression phases of the disease with the intent to
diagnose the disease in the earliest stage possible. This demands careful examination all
types of measures, structural, functional or metabolic, neuropsychological, demographic,
and genetic to assess which measures characterize the best progression from normal control to this early stage of mild cognitive impairment. There are current research efforts
that attempt at establishing new neuropsychological tests and new imaging techniques that
could even precede the EMCI phase [52]. Since EMCI can be considered as an earlier
state of mild cognitive impairment, it is of great significance to detect this state for potential early treatment planning and for designing subject-specific early curative/therapeutic
intervention protocols. The EMCI stage has shown a milder degree of cognitive impairment as compared to the MCI group, making this phase of the disease more amenable
to treatment or to a potential preventive process that will decelerate its progression and
provide a longer and better quality of life for these patients; recall the aforementioned
percentage of MCI patients that decline to AD.

So far, only a limited number of studies have considered EMCI and LMCI groups
[8, 53–59]. Prasad et al. proposed an SVM model to rank brain connectivity features
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based on their importance in the classification process [53]. Using diffusion-weighted
MRI together with connectivity metrics, an accuracy of 78.2% for CN vs. AD and of
59.2% for CN vs. EMCI classification were obtained by applying an SVM-based classification. They focused more on exploring features that are predictive of AD and used the
classification process to better assess the information attained through the connectivity
maps. Guerrero et al. reported a higher 65% accuracy for CN vs. EMCI classification
using data from the ADNI-GO dataset and making use of the sparse regression for variable selection and manifold learning as a classifier [56]. They used mini-mental state
examination (MMSE) instead of disease labels to have a more continuous correlation of
the disease stage and SVM with the linear kernel as the classification model.

Singh et al. proposed a feedforward deep neural network to perform classification
on fluorodeoxyglucose positron emission tomography (FDG-PET) [8]. They used probabilistic principal component analysis (PPCA) on max-pooled data from FDG-PET and
some demographic information including age, gender, APOE 𝜀1, and 𝜀2 alleles, and
functional activity questionnaire (FAQ). They achieved a maximum F1-score of 72% for
the CN vs. EMCI classification and a 98.14% accuracy for the CN vs. AD classification.
Goryawala et al. introduced a linear discriminative analysis (LDA) classifier with two-fold
cross-validation using MRI data, demographic information, and neuropsychological test
scores [54]. Using MRI features they achieved an accuracy of 61.6% for CN vs. EMCI
and 84.2% for CN vs. AD classification. Moreover [60] used MRI features combined
with MMSE to determine that the two most discriminative volumetric variables were the
right hippocampus and the left inferior lateral ventricle and when combined with MMSE
scores provided an average accuracy of 92.4% (sensitivity: 84.0%; specificity: 96.1%)
for AD vs. CN classification. Their results also show for amnestic MCI (aMCI) and
non-amnestic MCI (naMCI) that brain atrophy is almost evenly seen on both sides of the
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brain for AD subjects, which is different from right-side dominance for aMCI and left-side
dominance for naMCI. However, since the ADNI subject’s diagnosis is based on some
neuropsychological tests such as MMSE, involving this parameter trains the algorithm
based on clinical ground truth, which evidently increased the accuracy. Shakeri et al.
obtained an accuracy of 56% for the CN vs. EMCI classification on MRI data using a
multilayer perceptron (MLP) on top of a so-called deep variational autoencoder (VAE) for
feature selection and classification [59]. Guo et al. proposed an approach using functional
connectivity networks among different brain regions using fMRI data and a multi-kernel
SVM classifier that combines multiple variations of functional MRI (fMRI) data [58].
This approach resulted in an accuracy of 72.8% for the classification of the CN vs. EMCI
groups and 88.9% for the classification of the CN vs. AD groups; however, one drawback
of this study is that their results were based on a limited number of CN, EMCI, and AD
subjects (28 CN, 29 AD, and 33 EMCI). Jie et al. used multi-kernel SVM with t-test
feature selection algorithm for classification of fMRI data and obtained 66.0% accuracy
with 71.4% sensitivity for delineating the CN vs. EMCI [61].

This research endeavor develops the architecture for three machine learning platforms
that are based on (1) deep neural network (DNN), (2) support vector machine (SVM), and
(3) Gaussian process-based (GP) model classifiers all optimized in order to delineate the
different stages of the disease. Radial basis function (RBF) kernel is exploited for classifying four different groups of CN, EMCI, LMCI, and AD. For classification purposes,
a DNN approach is proposed for both binary and multiclass classification of CN, EMCI,
LMCI, and AD using multimodal neuroimaging (MRI and PET), and other measures
that include neuropsychological test scores and demographic data that includes age and
education level. In the developed algorithms, we used the Adam optimization technique
to update the DNN learning weights. To the best of our knowledge, there are but a handful
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of studies that report multiclass classification involving both EMCI and LMCI groups
included with the CN and AD groups. Our focus is on the delineation of the EMCI group
from the CN group due to the aforementioned importance of early detection, while most
studies focused on the MCI diagnosis, combining both EMCI and LMCI groups. We
propose a feature selection based on ranking the most important features to help clinicians
determine the most essential features in classifying the EMCI group using a large number
of subjects in the 4 groups (CN, EMCI, LMCI, AD) considered.

In addition to cross-sectional analysis for the classification of different groups, we
introduce a regression framework to predict the future cognitive status of individuals by
predicting their cognitive test scores using longitudinal data. Some neuropsychological tests have been designed to assess the clinical status of patients. The Mini-Mental
State Examination (MMSE), Clinical Dementia Rating (CDR), Alzheimer’s Disease Assessment Scale Cognitive Total Score (ADAS-cog), and Rey’s Auditory Verbal Learning
(RAVLT) are surrogate measures that can be predicted using neuroimaging in order to
gauge cognitive decline [62,63]. We present a regression analysis on a 4-year longitudinal
study as means to predict future cognitive scores in the trajectory of the disease. This type
of regression analysis could play a significant role in pre- and post-treatment evaluations
by assessing how disease trajectories are affected to see whether the decline is slowed by
such treatment or therapeutic intervention. The focus is placed on the early prediction of
conversion from the CN group to MCI with comparatively high accuracy. The challenges
for these two groups (CN, EMCI) are the subtle differences that exist between them not
only in terms of structural (MRI) functional or metabolic (PET) but also in terms of the
small differences that exist in their cognitive scores.
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In attempt to predict the brain structural and functional alternations across AD progression, several models have been proposed by researchers. Biomarkers Cascade Model
proposed by Jack et al. to predict the abnormalities of FDG- PET at least 24 months
before the onset of AD [64] and investigate the tau PET accumulation of the brain in
cognitively normal and AD groups [65]. A probabilistic approach based on random vector
field transformations has been applied on MRI in order to detect and visualize structural
abnormalities in AD and CN groups [66, 67]. A linear regression method was proposed
to predict the progression for one year from the MR image at baseline [68]. However, the
prediction of progression of Alzheimer’s especially in early stage or presymptomatic remains a challenge [69, 70]. One of the main challenges of early prediction of Alzheimer’s
is in the ability to decipher the variability and interrelatedness of the multimodal measurements. Moreover, there are two types of inter-subject variability related to brain changes
of the same subject in time and intra-subject variability associated with differences between subjects for the same variable. In addition, time spacing of data acquisition varies
even for the same subjects, and age of participants is not temporally aligned. Thus, the
unbalanced longitudinal data analysis, especially in multimodal approach could be most
challenging [6,68,71–74]. To overcome such challenges, a variety of approaches have been
proposed such as considering the age of participants [6], using cognitive scores [68, 74],
and creating a disease progression score [73, 75–78].

One challenge of longitudinal studies using neuroimaging data is the high dimensionality, which could lead to heavy computational requirements and an ineffective feature
selection process. Therefore, sparsity-inducing approaches have been proposed to better
identify the predictors by initially reducing the high dimensionality of the problem at
hand. Recently multitask learning with sparsity-inducing techniques have been extensively investigated through the shared representation of different tasks with the intent to
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minimize the prediction error and identify correctly the relevant features [79–81]. Most
of the multitask approaches assume that different tasks are related and share a common
set of features [82,83] or share a common subspace [84,85], or the tasks are clustered into
groups [86,87]. Wang et al. used 𝑙1 -norm regularizer to constrain the sparsity and applied
a combination of 𝑙1 -norm and 𝑙 2,1 -norm regularization to select a subset of features [80].
In another study, they used multitask learning at different time points of a 24-month time
period and utilized the lasso regularization in order to predict the MMSE and ADAS
scores [88]. A temporally constrained group sparse learning was proposed by Jie et al.
to predict ADAS and MMSE on longitudinal data for 24 months [89]. Liu et al. proposed a multi-task feature learning based on sparsity-inducing 𝑙 2,1 -norm to predict eleven
neuropsychological tests including MMSE based on MRI [90]. Cao et al. used 𝑙2,1 -norm
penalty applied on regression weights for feature selection and a group 𝑙2,1 -norm penalty
on MRI features to find the cognition-relevant brain regions in a shared subspace [91].
Later in 2018, they proposed a 𝑙2,1 , 𝑙1 -norm to improve the accuracy [92].

Although these single modality studies have merit in assessing the structural or functional alternations in the brain, they reveal that classification and prediction accuracy
could be enhanced by consolidating the strength each modality brings in a multimodal
processing approach [43, 91, 93–103]. A multimodal multitask learning with 𝑙2,1 -norm
was proposed by Zhang et al. which considered a common feature subset for related tasks
using a support vector regression to fuse the features of different modalities [79]. Xiang et
al. proposed a multisource sparse regression method focusing on missing modality issue
on cross-sectional data [104]. Zhou et al. proposed a multitask learning process which
considers the prediction of ADAS and MMSE at each time point in a task using MRI,
demographic information, and APOE genotype [105]. They used temporal group lasso
regularizer which consisted of two temporal smoothness processes and 𝑙2,1 -norm penalty
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term to ensure successive small deviation between regression models and selection of
small subset of variables at each time point, respectively. However, the limitation of this
study is that convex fused sparse group lasso (cFSGL) is considering two successive tasks
or time points which may lead to loosing task dependency between tasks or time points.

There are some studies that use prior knowledge regression models for intra-group
similarity using the group information [106, 107]. Nie et al. proposed an unsupervised
multisource multitask learning technique to learn MMSE and ADAS simultaneously by
using temporal smoothness and prior knowledge of source consistency [108]. However,
these methods have some limitations as the learning process for all tasks is done simultaneously for a common subset of brain regions while each task could be trained more
optimally using different brain regions. On the other hand, a common limitation that
many studies face is in assuming a linear relationship between predicted neuropsychological tests and the extracted neuroimaging measures. In addition, the majority of recent
studies were not able to address the missing data challenge, resorting instead to filling for
the missing values by interpolation techniques or removing subjects with missing data;
a process which ends up limiting the statistical meaningfulness of the study. Although
recent studies have considered MCI as the transitional stage from cognitively normal to
Alzheimer’s disease, this group remains the target of prediction in the progression to
AD. However, any treatment or therapy trials are likely to be more successful in the
earliest stage of the disease or even in the presymptomatic stage where no manifestation
of cognitive decline is yet apparent [48]. Therefore, identification of cognitively normal individuals who are likely to develop into MCI and potentially to AD could increase
the chances for intervening early with treatment or therapy and slow the progression of AD.
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In order to overcome the aforementioned challenges, a multimodal multitask learning
framework is proposed in chapter 5 by exploiting the graph Laplacian regularization as
it pertains to sparsity and by considering the task dependency matrix based on Gaussian
kernel across all tasks for modality-specific regression. This proposed framework uses
a kernel-based regression to investigate the relationship between neuroimaging features
and the neuropsychological tests as a nonlinear function, while simultaneously handling
the missing data challenge using the decision-tree based fusion. Furthermore, conversion
from both groups of CN and MCI are investigated the prediction outcomes of cognitive
test scores of MMSE, ADAS, and RAVLT in terms of root mean square error (RMSE)
and correlation coefficient (R2 ).
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CHAPTER 2
A DEEP NEURAL NETWORK APPROACH FOR EARLY DETECTION OF
MILD COGNITIVE IMPAIRMENT USING MULTIPLE FEATURES

2.1

Goal

This chapter proposes a machine learning approach based on a deep neural network
(DNN) in order to detect AD in its early stage using multimodal imaging, including
magnetic resonance imaging (MRI), positron emission tomography (PET) and standard
neuropsychological test scores. The proposed approach makes use of the optimization
method of Adam to update the learning weights to improve its accuracy. The algorithm
is able to classify the cognitively normal control group from early mild cognitive impairment (EMCI) with an unprecedented accuracy of 84.0%. Although the focus here is
distinguishing the two groups of CN and EMCI for early diagnosis and treatment planning, this study also shows how the proposed deep learning algorithm can be extended for
multiclass classification involving CN and all the stages of EMCI, late MCI (LMCI) and
AD. Our approach is able to diagnose EMCI with comparatively high accuracy both for
binary and multiclass modes. Based on our knowledge, this is the first time that multiclass
involving both EMCI and LMCI classification is reported. In addition, data pre-processing
is performed by extracting features from MRI and extracting standard uptake value ration
(SUVR) features from registered PET imaging.
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2.2
2.2.1

Materials and Methods
Data Acquisition

Data used in the preparation of this study are obtained from the Alzheimer’s Disease
Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). 1 The ADNI was launched
in 2003 as a public-private partnership, led by Principal Investigator Michael W. Weiner,
MD. The primary goal of ADNI has been to test whether serial magnetic resonance imaging (MRI), positron emission tomography (PET), other biological markers, and clinical
and neuropsychological assessment can be combined to measure the progression of mild
cognitive impairment (MCI) and early Alzheimer’s disease (AD). Identification of biological markers at the early stage of AD will help researchers and clinicians to plan for
early treatment and therapeutic interventions. The EMCI subject inclusion criteria are as
follows: MMSE scores between 24-30, CDR of 0.5, objective memory loss of 0.5-1.5 SD
(standard deviation) below normal according to the education adjusted scores on delayed
recall of one paragraph from Wechsler Memory Scale Logical Memory II, memory complaints, absence of the significant level of impairment in other cognitive domain, absence
of dementia, and essentially preserved activities of daily living. LMCI criteria are almost
similar to the EMCI except for the memory loss scores by Wechsler Memory Scale Logical
Memory II which is set at more than 1.5 SD below normal.

In this study, a total of 896 participants were classified into the four categories of CN
(248), AD (159), EMCI (296), and late mild cognitive impairment (LMCI) (193). All
1Data used in the preparation of this article were obtained from the Alzheimer’s
Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu).
As such, the investigators within the ADNI contributed to the design and implementation of ADNI
and/or provided data but did not participate in the analysis or writing of this report.
A complete listing of ADNI investigators can be found at: http://adni.loni.usc.edu/wpcontent/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf
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subjects had an MRI and a Florbetapir (18F-AV-45) amyloid PET scan within a 6-month
time window. Table 2.1 shows the details of the demographic information of the subjects
used in this study. In this research endeavor, we combined the neuroimaging data with
some neuropsychological test scores of the subjects, which include Rey’s auditory verbal
learning test (RAVLT) as a well-known test for episodic memory, Montreal cognitive assessment (MoCA) known to be effective in the setting of mild cognitive impairment, and
everyday cognition total (ECogT) which is associated with measures of global cognition
and functional status. Table 2.2 provides the neuropsychological test information of the
participants that are used in this study.

Table 2.1: Demographic information of the participants
CN
EMCI
LMCI
AD
Number of subjects 248
296
193
159
Female/Male
125/123 132/164 84/109
67/92
*
Age-PET(year)
75.7(6.5) 71.5(7.4) 73.8(8.1) 74.9(7.8)
Age-MRI (year)
75.2(6.5) 71.3(7.4) 73.6(8.1) 74.7(7.8)
Years of Education 16.4(2.5) 15.9(2.6) 16.2(2.7) 15.7(2.7)
* Values

illustrate mean (standard deviation) for all attributes

Table 2.2: Neuropsychological information of the Participants (PF: Percent-Forgetting,
Im: Immediate)
CN
EMCI
MoCA
25.7(2.5) 24(2.8)
ECogT
1.2(0.3)
1.6(0.5)
RAVLT-PF 36.2(20.5) 47(30)
RAVLT-Im 45.3(10.5) 40(10.6)

2.2.2

LMCI
22.4(3.3)
1.9(0.7)
67.2(31.5)
33.2(11)

AD
17.2(4.5)
2.8(0.6)
89.4(20.5)
22.7(7)

MRI Processing

MRI images are 3T T1-weighted using a 3D sagittal volumetric magnetization prepared rapid gradient echo (MP-RAGE) sequence. Here, the repetition time is 2,300 𝑚𝑠,
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minimum full echo time, inversion time is 900 𝑚𝑠 with a 256 × 256 × 170 acquisition matrix providing a voxel size of 1.0 × 1.0 × 1.2 𝑚𝑚 3 . In this study, the T1-weighted standard
MNI 305 space MRI has been used to do feature extraction using FreeSurfer version 5.3.
The T1-weighted image was used as the reference image in the registration process, which
included skull-striping, segmentation, and demarcation of the different brain regions.

We extracted 3 measurements that included mean intensity, volume, and intensity
standard deviation after dividing the image into 45 subcortical regions. In addition, 9
morphological variables including gray matter volume, rectified mean curvature, folding
index, surface area, intrinsic curvature index, average thickness, rectified Gaussian curvature index, white matter volume, and thickness standard deviation for 68 cortical regions
were generated. Furthermore, the estimated total intracranial volume (eTIV) is calculated,
which is used later for normalization of the volumetric measures.

2.2.3

AV-45 PET Processing

PET images used in this study were acquired of 370 MBq (10 mCi), dynamic 3D scan
of four 5-minute frames from 50 to 70 minutes post-injection, co-registered, averaged,
reoriented into a standard 160 × 160 × 96 voxel image grid with 1.5 𝑚𝑚 cube voxels, and
smoothed to a uniform isotropic resolution of 8 𝑚𝑚 full width of maximum. In order to
acquire the standard uptake value ratio (SUVR) for each participant’s amyloid accumulation, first, the AV-45 PET scan was linearly registered onto the T1-weighted image using
FSL [109] with 12 degrees of freedom (DoF). The steps of feature extraction from MRI
and PET data through image processing are illustrated in the early part of Figure 2.1.
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Figure 2.1: Overall diagram of the proposed DNN Classifier.

The registration phase plays an important role to get as much information as possible
from PET scan due to the low resolution of this neuroimaging technique. This registration
process provides the same MRI parcellation and segmentation for the AV-45 PET image.
Then the mean intensity of each FreeSurfer region (ROI) for the 45 subcortical and the
68 cortical regions were assessed, which together identify the standardized uptake values
(SUVs). These values extracted from each region were obtained by volume-weighted
means as in Equation (2.1).

𝑛
Í

𝐼𝑗

𝑗=1

(2.1)

𝑆𝑛 =
𝑀

where 𝑆𝑛 is the mean SUV of region 𝑛, with 𝑀 defining the number of voxels found
in region 𝑛, and 𝐼 𝑗 is the intensity of voxel 𝑗 in the AV-45 PET. The whole cerebellum
SUV including 4 subcortical regions (right/left cerebellum and right/left white matter)

17

and global uptake value consisting of 68 cortical ROIs (34 ROIs for each hemisphere)
were calculated as follows:

𝑆𝐶 𝑅 =

𝑆 𝑅1 × 𝑉𝑅1 + 𝑆 𝑅2 × 𝑉𝑅2 + ... + 𝑆 𝑅 𝑘 × 𝑉𝑅 𝑘
𝑉𝑅1 + 𝑉𝑅2 + ... + 𝑉𝑅 𝑘

(2.2)

where the 𝑆𝐶 𝑅 represents the SUV of combined 4 cerebellum and 68 cortical regions, 𝑆 𝑅𝑖
defines the SUV corresponding to region 𝑅𝑂𝐼𝑖 and 𝑉𝑅𝑖 is a measure of the volume of 𝑅𝑂𝐼𝑖 .
In the end, all the computed global SUVs were normalized by the whole cerebellum SUV
as the reference to compute standard uptake value ratio (SUVR) as expressed in Equation
(2.3).

𝑆𝑈𝑉 𝑅 =

2.2.4

𝐺𝑙𝑜𝑏𝑎𝑙 𝑆𝑈𝑉
𝑅𝑒 𝑓 𝑒𝑟𝑒𝑛𝑐𝑒 𝑆𝑈𝑉

(2.3)

Statistical Analysis

As mentioned before, one of the challenges of neuroimaging analysis is the high dimensionality of data, specifically in AD and MCI diagnosis with low samples. Therefore,
feature selection plays an important role in preprocessing the data. This study is based on
10-fold cross-validation for better reliability of the system. Analysis of variance (ANOVA)
was applied to the training data to calculate the variances of groups which is followed by
Bonferroni correction to adjust the P-values (threshold of P-value is 0.05 in this study).
Then the correlation of each feature is computed and the highly correlated features were
removed for dimensionality reduction purpose. The network was thus tested using the test
data and the model achieved from the training process.
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2.2.5

Feature Normalization

In this study, we used feature-wise scaling in order to normalize the data and increase
the accuracy of classification. For this purpose, each feature linearly transformed to have
unit standard deviation and zero mean as follow:
𝑥𝑁 = (

𝑥 − 𝑥¯
)
𝑠𝑡𝑑

(2.4)

where 𝑠𝑡𝑑 represents the standard deviation of each feature vector, 𝑥 represents the feature
vector, 𝑥 𝑁 defines each normalized feature vector, and 𝑥¯ represents its mean value.

2.2.6

Deep Neural Network

A deep neural network (DNN) can be obtained by increasing the number of hidden
layers. In this study, we used 3 hidden layers. In addition, to tackle the overfitting problem,
we used the so-called dropout technique [110]. The main idea in the dropout technique
is to randomly eliminate (drop out) units (along with their connections) from the DNN
during the training process to prevent units from too much co-adapting. This technique
helps to significantly reduce the burden of overfitting and yields major advantages in
terms of computational requirements and the resulting outcome in comparison with other
regularization approaches. The block diagram of the proposed classification algorithm
along with feature extraction steps are presented in Figure 2.1.

Here, we used the DNN structure using backpropagation where its learning weights
are getting updated with adaptive moment estimation. Adam is an efficient method that
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has advantages of both RMSProp and AdaGrad [111]. The weights update rules for the
iteration 𝑡 for the initial values 𝑀0 = 0, 𝑅0 = 0, 𝑀𝑏0 = 0, and 𝑅𝑏0 = 0 are as follows:
𝑀𝑡 = 𝛼1 𝑀𝑡−1 + (1 − 𝛼1 )𝜃 𝑡
𝑀𝑏𝑡 = 𝛼1 𝑀𝑏𝑡−1 + (1 − 𝛼1 )𝜃 𝑏𝑡

(2.5)

𝑅𝑡 = 𝛼2 𝑅𝑡−1 + (1 − 𝛼2 )𝜃 𝑡2
𝑅𝑏𝑡 = 𝛼2 𝑅𝑏𝑡−1 + (1 − 𝛼2 )𝜃 2𝑏𝑡

where 𝑀𝑡 and 𝑀𝑏𝑡 are the weights and bias for the momentum, 𝛼1 is the hyperparameter for the momentum, 𝑅𝑡 and 𝑅𝑏𝑡 are the weights and bias for RMSProp, and 𝛼2
is the hyper-parameter for the RMSProp. Here, 𝛼1 and 𝛼2 are equal to 0.99 and 0.999,
respectively. 𝜃 𝑡 , 𝜃 𝑏𝑡 are the gradients for the weight and bias. In addition, 𝜃 𝑡2 indicates
Ç
𝜃𝑡
𝜃 𝑡 using the mini-batch gradient. In the next step, the corrected weights can be
computed as follows:
𝑀ˆ 𝑡 = 𝑀𝑡 /(1 − 𝛼1𝑡 )
𝑀ˆ 𝑏𝑡 = 𝑀𝑏𝑡 /(1 − 𝛼1𝑡 )

(2.6)

𝑅ˆ𝑡 = 𝑅𝑡 /(1 − 𝛼2𝑡 )
𝑅ˆ 𝑏𝑡 = 𝑅𝑏𝑡 /(1 − 𝛼2𝑡 )
Finally, the weights and biases are getting updated as follows:

𝑣 𝑡 = 𝑣 𝑡−1 .𝜂.√︁
𝑏 𝑡 = 𝑏 𝑡−1 .𝜂.√︃

𝑀ˆ 𝑡

𝑅ˆ𝑡 + 𝜖
𝑀ˆ 𝑏𝑡

(2.7)

𝑅ˆ 𝑏𝑡 + 𝜖

where 𝑣 𝑡 represents the weights of the DNN, 𝑏 𝑡 represents the biases, 𝜖 is a parameter to
prevent any division by zero which is considered 10−8 and 𝜂 is learning rate equal to 0.001
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in this study. One advantage of Adam is choosing the stepsize very carefully which can
be computed as
𝜂. 𝑀ˆ 𝑡
Δ𝑡 = √︁
𝑅ˆ𝑡 + 𝜖

(2.8)

The stepsize in Adam rule has 2 upper bounds as follows:

√


| Δ𝑡 |≤ 𝜂 (1 − 𝛼1 ) / 1 − 𝛼2













| Δ𝑡 |≤ 𝜂

√
if (1 − 𝛼1 ) > 1 − 𝛼2
(2.9)
otherwise

where Δ𝑡 is the stepsize, 𝛼1 and 𝛼2 ∈ (0, 1) are exponential decline rates in order to
estimate the moment. The activation function, 𝜎(.), used is sigmoid defined as
𝜎(𝑥) =

2.3

1
1 + 𝑒 −𝑥

(2.10)

Results and Discussion

In this study, a deep neural network classifier was applied to the multimodal MRI
and PET imaging with the focus placed on the diagnosis of EMCI from CN subjects.
The binary classification results for 6 different groups using multimodal imaging are
listed in Table 2.3. It is clear from these results that the combination of demographic
information and neuropsychological test scores (NTS) of the participants together with
MRI and PET imaging modalities enhances the accuracy of the classification significantly.

Figure 2.2 displays the ROC associated with the participants given in Table 2.3. As it
can be seen, a classification accuracy of 84.0% and sensitivity of 83.2% have been achieved
for classification of EMCI and cognitively normal subjects using all the available information of participants, while the best accuracy of 68% for CN vs. EMCI using MRI and PET
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modalities alone. Moreover, the accuracy of 96.8% and 84.1% for CN vs. AD and CN vs.
LMCI were achieved, respectively; which are higher than most of the results obtained from
previous studies. In addition, Table 2.4 and Figure 2.3 provides the comparison between
the proposed deep neural network and neural network with one hidden layer with the
same number of all nodes in DNN. It is obvious that DNN is more successful for the classification of CN vs. EMCI, LMCI, and AD considering the accuracy and AUC of the ROC.

Table 2.3: Accuracy (Acc), Sensitivity (Sen), and Specificity (Spe) of the DNN classifier
for different pairs of binary classification. NTS represents the Neuropsychological Test
Scores of RAVLT, ECogT, and MoCA. The values are represented as a percent)

MRI
PET
MRI+PET
MRI+PET+NTS*

MRI
PET
MRI+PET
MRI+PET+NTS

CN vs. EMCI
Acc Sen Spe
61.1 66.5 58.7
58.2 66.1 48.6
68.0 73.1 63.8
84.0 83.2 84.4
EMCI vs. LMCI
Acc Sen Spe
62.6 71.3 52.5
58.8 74.2 41.3
68.2 78.1 57.5
69.5 80.6 60.5
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CN vs. LMCI
Acc Sen Spe
64.1 53.2 70.2
66.0 54.4 76.0
71.7 60.1 80.9
84.1 80.4 87.6
EMCI vs. AD
Acc Sen Spe
77.1 80.2 71.1
78.0 83.1 65.4
83.2 80.0 86.7
90.3 86.7 92.2

CN vs. AD
Acc Sen Spe
82.2 75.0 87.3
88.9 85.7 90.3
89.6 88.9 90.1
96.8 94.1 98.2
LMCI vs. AD
Acc Sen Spe
61.5 63.6 62.0
64.5 73.4 54.4
68.4 74.1 68.8
80.2 86.8 71.9

1

0.9

0.8

True Pasitive Rate

0.7

0.6

EMCI + NTS (AUC: 0.90)

0.5

LMCI + NTS (AUC: 0.91)

0.4

AD + NTS (AUC: 0.98)
EMCI (AUC: 0.76)

0.3

LMCI (AUC: 0.77)
AD (AUC: 0.97)

0.2

0.1

0
0

0.1

0.2

0.3

0.4

0.5

0.6

0.7

0.8

0.9

1

False Pasitive Rate

Figure 2.2: ROC curve and area under the curve (AUC) of CN vs. EMCI, LMCI, and AD
with and without using neuropsychological test scores for the proposed DNN.

Table 2.4: Accuracy (Acc), Sensitivity (Sen), and Specificity (Spe) of the ANN classifier
CN vs. EMCI
Acc Sen Spe
MRI
59.6 74.8 41.9
PET
61.1 69.5 50.9
MRI+PET
64.8 69.3 57.1
MRI+PET+NTS 81.1 84.4 83.1
EMCI vs. LMCI
Acc Sen Spe
MRI
59.2 69.3 47.0
PET
62.3 78.2 40.0
MRI+PET
61.5 70.1 51.3
MRI+PET+NTS 67.1 79.4 52.1
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CN vs. LMCI
Acc Sen Spe
61.0 53.3 71.7
65.4 56.7 71.7
67.4 58.6 76.9
82.3 78.4 86.5
EMCI vs. AD
Acc Sen Spe
76.3 70.0 75.1
74.0 66.6 84.1
79.2 74.2 87.5
88.6 83.8 92.5

CN vs. AD
Acc Sen Spe
80.9 80.9 80.2
86.4 81.1 90.3
89.1 87.4 92.1
93.4 91.5 95.1
LMCI vs. AD
Acc Sen Spe
61.2 67.5 54.2
64.9 68.0 57.4
66.9 68.8 66.2
79.1 81.9 76.1

1

0.9

0.8

True Positive Rate

0.7

0.6

0.5

ANN:EMCI+NTS (AUC: 0.85)
ANN: AD+NTS (AUC: 0.93)
ANN:EMCI (AUC: 0.70)

0.4

ANN: AD (AUC: 0.94)
DNN:EMCI+NTS (AUC: 0.90)

0.3

DNN: AD+NTS (AUC: 0.98)
DNN: EMCI (AUC: 0.76)
DNN: AD (AUC: 0.97)

0.2
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1
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Figure 2.3: ROC curve and AUC values of CN vs. EMCI and CN vs. AD with and
without using neuropsychological test scores for both ANN and DNN.

Furthermore, Table 2.5 shows the accuracy resulting from multiclass classification
and the classification accuracy for delineating each group from other different groups for
ANN and DNN. Although the results for binary classification in some groups are almost
similar in ANN and DNN, the accuracy in multiclass classification is higher in the deep
neural network; besides, Figure 2.3 indicates that DNN has higher AUC values than ANN,
which proves the advantages of DNN over ANN. Here, we used 𝑜𝑛𝑒 𝑣𝑠. 𝑎𝑙𝑙 approach of
multiclass classification. Based on our own knowledge, this is the first report of multiclass
CN, EMCI, LMCI, and AD classification. Another important point in this study is the
high sensitivity in both multiclass and binary classification that were obtained in the EMCI
diagnosis. In binary mode, the EMCI was set as the positive class in all pairs.
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Table 2.5: Comparing the DNN classifier with ANN considering the overall accuracy
(Acc), accuracy of CN detection (Ac1), accuracy of EMCI detection (Ac2), accuracy of
LMCI detection (Ac3), and accuracy of AD detection (Ac4) for different groups of one
vs. all classification (all the values are in percent and rounded to the nearest integer)

ANN
DNN
ANN + NTS
DNN + NTS

ANN
DNN
ANN + NTS
DNN + NTS

CN/EMCI/LMCI
Acc Ac1 Ac2 Ac3 Ac4
42 39 43 40 51 48 57 47 55 69 57 43 60 66 62 50 EMCI/LMCI/AD
Acc Ac1 Ac2 Ac3 Ac4
51 - 65 30 53
54 - 66 35 55
57 - 65 38 69
59 - 73 45 68

CN/EMCI/AD
Acc Ac1 Ac2 Ac3 Ac4
60 57 55 - 75
61 58 57 - 75
65 62 58 - 81
68 66 63 - 78
CN/EMCI/LMCI/AD
Acc Ac1 Ac2 Ac3 Ac4
43 47 48 25 48
46 52 50 31 53
52 68 50 28 61
57 61 59 39 66

CN/LMCI/AD
Acc Ac1 Ac2 Ac3 Ac4
55 69 - 33 60
59 72 - 43 59
64 77 - 48 65
70 82 - 49 74

Table 2.6 provided an assessment of our proposed in comparison to related studies,
where it can be clearly seen that the proposed method yielded a higher accuracy in almost
all the binary classification, and to the best of our knowledge, it is the first study of its
kind to report both binary and multiclass classification involving all the groups of CN,
EMCI, LMCI, and AD. Goryawala et al. reported the accuracy of 61.6% for CN vs.
EMCI classification based on MRI and accuracy of 85.6% for the same groups based on a
combination of the MRI data with some neuropsychological tests like MMSE using linear
discriminative analysis (LDA) [54]. However, since MMSE is one of the most important criteria for diagnosis in ADNI, involving these parameters means that the algorithm
is trained using initially the clinical ground truth. In order to prevent circulation in our
method, we tried not to involve the diagnosis parameters of ADNI such as the MMSE score.

Figure 2.4 shows the effects of different tests on three groups of CN vs. EMCI, CN
vs. LMCI, and CN vs. AD based on changes in accuracy. We observed that using the
RAVLT, ECogT, and MoCA test scores affected the EMCI classification more than any
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Table 2.6: Accuracy (Acc) of the DNN classifier comparing to the previous works
Modality
[59]
[53]
[56]
[54]
Proposed
Proposed

[59]
[53]
[56]
[54]
Proposed
Proposed

CN vs. EMCI
Accuracy (%)
MRI
56
Diffusion MRI
59.2
MRI
65
MRI
61.6
MRI+PET
68.0
MRI+PET+NTS 84.0
Modality
EMCI vs. LMCI
Accuracy (%)
MRI
63
Diffusion MRI
63.4
MRI
MRI
68.8
MRI+PET
68.2
MRI+PET+NTS 69.5

CN vs. LMCI

CN vs. AD

59
62.8
71.4
71.7
84.1
EMCI vs. AD

84
78.2
86
84.2
89.6
96.8
LMCI vs. AD

81
81.4
83.2
90.3

67
59.6
68.4
80.2

other groups based on increasing the accuracy. However, these tests affected the LMCI
classification more than any other groups based on increasing the sensitivity as shown in
Table 2.3. Using NTS improves the classification accuracy of CN vs. EMCI by almost
16% and CN vs. LMCI by 13% but only by 5% for the CN vs. AD classifications;
however, improves the sensitivity of CN vs. LMCI by 20% and CN vs. EMCI by 10%.

It is obvious that among these neuropsychological tests, RAVLT immediate and ECogT
contributed more effectively to the EMCI diagnosis. RAVLT scores are capable of reflecting the underlying pathology caused by AD very well and ECogT has contributed to the
global cognition and functional status. Therefore, RAVLT and ECogT can be considered
as effective early markers for diagnosing the prodromal stage of MCI in people who have
memory complaints. In addition, RAVLT percent-forgetting is more contributed to LMCI
diagnosis.
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Figure 2.4: Importance of different neuropsychological test scores for three groups of CN
vs. EMCI, CN vs. LMCI, and CN vs. AD classifications.
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CHAPTER 3
EARLY DIAGNOSIS OF MILD COGNITIVE IMPAIRMENT USING SUPPORT
VECTOR MACHINE

3.1

Goal

This chapter proposes a new feature selection algorithm to find the most relevant
features. The aim is to use a support vector machine (SVM) approach with radial basis
function (RBF) in order to detect AD in its early stage using multiple modalities, including
PET, MRI, and standard neuropsychological test scores. A total number of 896 participants
were considered in this study. The proposed approach is able to classify cognitively normal
control (CN) group from early mild cognitive impairment (EMCI) with an accuracy of
81.1%. In addition, the accuracy of 91.9% for CN vs. late mild cognitive impairment
(LMCI) and an accuracy of 96.2% for CN vs. AD classifications were achieved through
the proposed model.

3.2
3.2.1

Materials and Methods
Data Acquisition

In this study, we used the same pre-processed data as in Chapter 2. A total number
of 896 participants were categorized into four groups of EMCI (296), LMCI (193), CN
(248), and AD (159). The overall design architecture of the proposed method is depicted
in Figure 3.1.
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Figure 3.1: Diagram of the preprocessing step and the proposed classification.

3.2.2

Feature Selection

The main challenge in analyzing high-dimensional data is the existence of a very large
number of features or variables that may not all be associated with the disease and could be
contributing differently at any given phase of the disease. This problem is made even more
difficult when the database suffers from a low sample size. Hence, dimensionality reduction techniques or selection of prominent features can play an essential role in machine
learning when seeking optimal classification results [112, 113]. In addition, the ranking
of these prominent or most relevant features can be appraised whenever the classification
results in delineating challenging groups have been optimized, especially when the most
subtle of changes differentiate them (like in CN vs. EMCI). These features are deemed
relevant only because they do indeed reflect these subtle changes albeit at varying degrees.
An optimal decision-making process needs to be established when applying dimension
reduction techniques to guarantee that the relevant features are maintained. Although there
is a probability to remove some relevant features during feature reduction [114]; however,
feature selection techniques are successfully used especially for kernel-based techniques
such as SVM [115, 116].
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In this study, first, we divided the data into 80% training and 20% testing data and
then applied the feature selection process only on training data and assessed the model
on the 20% remaining test data. Due to the fact that the random forest (RF) method
is time-consuming, we applied ANOVA on the whole training data for each pairwise
group separately to reduce the dimensionality considering a P-value of 0.05. Then, we
used the RF model to obtain the most important features. Random forest is a tree-based
approach, which facilitates multimodal imaging classification by deriving the similarity
measures [117]. The RF model combines re-sampling and random feature selection to
construct the trees for both classification and regression purposes. On the other hand,
RF methodology can provide the hierarchical importance of the different features using
statistical permutation and Gini impurity index [118]. The Gini importance score is a
measure of variable relevance based on impurity reduction. The Gini impurity, 𝐺 (𝑛), can
be calculated as follows

2
2
𝐺 ( 𝑗) = 1 − 𝑓+1
− 𝑓−1

where 𝑓𝑛 =

𝑘𝑛
𝑘

(3.1)

defines the ratio of the 𝑘 𝑛 samples from the binary class out of the total

samples 𝑘 at the specific node of 𝑗. Then, the reduction of Gini impurity, Δ𝐺 ( 𝑗) resulting
from splitting the samples to 𝑗 𝑙 and 𝑗𝑟 sub-nodes are then calculated as in Equation (3.2)

Δ𝐺 ( 𝑗) = 𝐺 ( 𝑗) − 𝑓𝑙 𝐺 ( 𝑗 𝑙 ) − 𝑓𝑟 𝐺 ( 𝑗𝑟 )

(3.2)

where 𝑙 and 𝑟 subscripts specify the left and right sub-nodes at each sample splitting. The
fraction of data points for the left and right subsets 𝑓𝑙 and 𝑓𝑟 are defined as 𝑓𝑙 =
𝑓𝑟 =

𝑘𝑟
𝑘 .

𝑘𝑙
𝑘

and

Finally, the Gini Index as an indicator for the selection of feature 𝐹 is calculated

based on aggregating the impurity reduction Δ𝐺 ( 𝑗, 𝑇) for the nodes 𝑗 and trees 𝑇 as follow
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𝐼𝑛𝑑𝑒𝑥(𝐹) =

∑︁ ∑︁
𝑇

Δ𝐺 𝐹 ( 𝑗, 𝑇)

(3.3)

𝑗

The random forest feature elimination approach is implemented as in the given steps
below. First, the algorithm is applied using all variables including age, education, structural and functional variables extracted from the MRI, PET imaging modalities. If we
consider 𝑝 as a sequence of probable number of variables to retain (𝑝 1 > 𝑝 2 > ...), at each
iteration the variables are ranked based on the explained below process and the top-ranked
variables 𝑝 𝑗 are maintained. The performance of the model is evaluated and the number
of variables is determined. Then using the 10-fold cross-validation resampling approach,
the above process is encapsulated in one iteration of resampling. This process is repeated
for every iteration of 10-fold cross-validation. Then the subsets with the highest accuracy
for each iteration were selected and gathered in a pool. In the next step, the features were
selected based on the most votes obtained. The RF feature selection model is demonstrated
below:

Random Forest Feature Selection

1. for each iteration of 10-fold cross-validation
• Partition the train data into training and testing sets
• Train the random forest model using the training set
• Assess the performance of the model on the testing set
• Rank the variables according to their importance
• for each subset of variable numbers 𝑝 𝑗 for 𝑗 = 1, 2, ..., 𝑝
– Retain the 𝑝 𝑗 highest-ranked variables
– Train the RF model on the training set using 𝑝 𝑗 variables
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– Assess the performance of the model
– Recalculate the importance of each variable
– Repeat the process since no variables can be removed
• end
2. end
3. Choose the subsets with the highest accuracy in each iteration
4. Gather all selected subsets in a pool and select the variables based on the most votes
obtained
5. Specify the number of variables
6. Fit the model
In the end, we applied correlation versus class labels to the data in order to prevent
the algorithm from overfitting by training with too many features. The features with
the highest absolute value of correlation are selected based on the Pearson’s correlation
coefficient.

3.2.3

SVM model

The SVM-based classifier was originally introduced by Vapnik [119] and has been
widely used in classification problems due to their robust performance in the presence
of noisy data. In SVM, a set of training data defined as: (𝑦 1 , 𝑥 1 ), ..., (𝑦 𝑘 , 𝑥 𝑘 ), can be
Í𝑘
0 𝑥 . By
partitioned by the hyperplane of (𝑤 0 , 𝑥) + 𝑏 0 = 0, where 𝑤 0 = 𝑚=1
𝑦 𝑚 𝜂𝑚
𝑚
substituting 𝑤 0 into hyper plane equation, the nonlinear classifier rule can be described as
a linear combination of kernels associated with the support vectors as [120]:
𝑘
∑︁

0
𝜂𝑚
𝑦 𝑚 𝐾 (𝑥, 𝑥 𝑚 ) + 𝑏 0 = 0

𝑚=1
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(3.4)

where 𝑦 𝑚 ∈ {−1, +1} is the corresponding class label, 𝑥 𝑚 is the training pattern, 𝑏 0 is the
offset error, 𝑘 is the number of training samples, and 𝐾 is the kernel. 𝜂 is the Lagrange
0 is the solution of the following quadratic optimization problem:
multiplier, and 𝜂𝑚

𝑘
1 ∑︁
𝜂𝑚 𝜂𝑛 𝑦 𝑚 𝑦 𝑛 𝐾 (𝑥 𝑚 , 𝑥 𝑛 )
(3.5)
2
𝑚,𝑛=1
𝑚=1
Í𝑘
which is subjected to the following constraints: 𝑚=1
𝑦 𝑚 𝜂𝑚 = 0, 0 ≤ 𝜂𝑚 ≤ 𝐶, (𝑚 =

𝑊 (𝜂) =

𝑘
∑︁

𝜂𝑚 −

1, ..., 𝑘), where 𝐶 is the parameter used to penalize the classification error. In this work,
we used Gaussian kernel also known as radial basis function (RBF) [121], that can be
computed by Equation (4.4) as follows:
[𝐾] 𝑚,𝑛 = 𝑒𝑥 𝑝(−

3.3

k (𝑥 𝑚 − 𝑥 𝑛 ) k 2
)
𝜎2

(3.6)

Results

In this study, an SVM classifier was applied to the multimodal MRI and PET imaging
system with a focus on delineating the EMCI group from the CN group. The results for six
different binary classifications using multimodal imaging are listed in Table 3.1. It is clear
from these results that the combination of demographic information and neuropsychological test scores (NTS) of the participants together with MRI and PET imaging modalities
enhances the accuracy of the classification significantly. As it can be seen from Table
3.1, a classification accuracy of 81.1%, a sensitivity of 82.8% and a specificity of 79.8%
have been achieved for classification of EMCI and CN subjects using all the available information of participants. For the classification of subtle changes that exist between such
groups (CN, EMCI), these results provide credence to the proposed approach. Moreover,
the accuracy of 91.9% and 96.2% for CN vs. LMCI and CN vs. AD were achieved,
respectively.
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Table 3.1: Accuracy (Acc), Sensitivity (Sen), and Specificity (Spe) of the SVM classifier
for different pairs of binary classification (values are represented as percent)

MRI
PET
Proposed
Proposed+NTS **

MRI
PET
Proposed
Proposed+NTS
* -:

CN vs. EMCI
Acc Sen Spe
73.1 76.8 68.4
-*
- 75.6 78.9 70.6
81.1 82.8 79.8
EMCI vs. LMCI
Acc Sen Spe
70.1 81.1 55.0
63.9 42.1 78.0
70.1 80.0 60.0
71.5 81.3 63.0

CN vs. LMCI
Acc Sen Spe
63.0 61.5 69.9
73.6 69.5 83.7
76.9 70.0 85.7
91.9 82.4 97.9
EMCI vs. AD
Acc Sen Spe
84.7 89.8 80.7
70.8 87.6 55.6
85.5 90.5 80.8
93.2 98.0 80.0

CN vs. AD
Acc Sen Spe
90.3 90.3 91.8
82.5 79.7 83.7
91.2 90.1 93.9
96.2 93.3 97.9
LMCI vs. AD
Acc Sen Spe
65.2 60.5 70.0
73.2 76.4 61.3
78.3 76.3 80.6
80.2 76.3 86.2

No data available
Neuropsychological Test Scores of RAVLT, ECogT, and MoCA

** NTS:

Figure 3.2 displays the ROC and area under the curve (AUC) associated with the
classification results in Table 3.1. The AUC of 0.81, 0.80, and 0.96 are obtained for
classification of CN vs. EMCI, CN vs. LMCI, and CN vs. AD, respectively without
involving the cognitive tests as well as AUC of 0.88, 0.98, and 0.99 for classification of
CN vs. EMCI, CN vs. LMCI, and CN vs. AD, respectively with the combination of
neuroimaging features and cognitive tests.

Figure 3.3 shows the importance of every neuropsychological test scores based on
sensitivity changes for three groups of CN vs. EMCI, CN vs. LMCI, and CN vs. AD.
We observed that using the NTS including RAVLT, ECogT and MoCA affected the LMCI
classification more than any other groups. It is evident from Table 3.1, using NTS improves the accuracy of CN vs. LMCI by almost 15% but only by 6% for the CN vs. EMCI
and by 5% for the CN vs. AD classifications.
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Figure 3.2: ROC curve and AUC of three classifications of CN vs. EMCI, CN vs. LMCI,
and CN vs. AD using NTS and without using NTS.
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Figure 3.3: Impact of neuropsychological test scores (NTS) used in this study for three
classifications of CN vs. EMCI, CN vs. LMCI, and CN vs. AD separately. (PF: PercentForgetting, Im: Immediate)
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We found that among these neuropsychological tests, ECogT contributed more effectively to the LMCI and RAVLT percent-forgetting to the EMCI diagnosis. MoCA also
enhances the classification accuracy of CN vs. LMCI significantly while, interestingly,
RAVLT immediate and RAVLT percent-forgetting have no impact on both CN vs. EMCI
and CN vs. LMCI classifications, respectively. RAVLT scores are capable of reflecting
the underlying pathology caused by AD very well. Therefore, RAVLT percent-forgetting
can be considered as an effective marker for the detection of the early stage of Alzheimer’s
disease in patients who have memory complaints. In addition, ECogT which is associated with global cognition and functional status is also a useful clinical tool for early
and late diagnosis of MCI. It is obvious that CN vs. AD is more affected by RAVLT
percent-forgetting in comparison with the other tests. Table 3.2 provides an assessment of
our proposed approach in comparison to related studies, where it can be clearly seen that
the proposed method with and without neuropsychological test scores yielded a higher
accuracy in almost all the binary classification groups.

Table 3.2: Accuracy (Acc) of the proposed method compared to the previous studies of
EMCI and LMCI
CN vs. EMCI
[59]
56
[53]
59.2
[56]
65
[58]
72.8
Proposed
75.6
proposed+NTS 81.1
EMCI vs. LMCI
[59]
63
[53]
63.4
[56]
[58]
Proposed
70.1
proposed+NTS 71.5
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CN vs. LMCI
59
62.8
78.6
76.9
91.9
EMCI vs. AD
81
85.5
93.2

CN vs. AD
84
78.2
86
88.9
91.2
96.2
LMCI vs. AD
67
78.3
80.2

CHAPTER 4
A GAUSSIAN-BASED MODEL FOR EARLY DIAGNOSIS OF MILD
COGNITIVE IMPAIRMENT USING MULTIMODAL NEUROIMAGING

4.1

Goal

This chapter develops a random forest feature selection model with a Gaussian-based
classifier. This integrated method serves to define multivariate normal distributions in
order to classify different stages of AD, with the focus placed on detecting EMCI subjects
in the most challenging classification of CN vs. EMCI. Using 896 participants classified
into the four categories of CN, EMCI, LMCI, and AD, the results show that the EMCI
group can be delineated from the CN group with a relatively high accuracy of 78.8% and
sensitivity of 81.3%. Moreover, the performance of the feature selection model and the
Gaussian process-based classifier are compared to other state-of-the-art algorithms. The
proposed method outperformed others such as minimum redundancy maximum relevance
(MRMR) and t-test feature selection methods.

4.2
4.2.1

Materials and Methods
Data Acquisition

In this study, we used the same preprocessed data as in chapter 2. A total number
of 896 participants were categorized into four groups of EMCI (296), LMCI (193), CN
(248), and AD (159). The overall view of the proposed method is depicted in Figure
4.1. The same feature selection method as chapter 3 was applied to the data in order to
assess the performance of the proposed feature selection and classifier with other methods.
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Figure 4.1: Neuroimaging feature extraction and overall diagram of the proposed method.

4.3

Gaussian Process

Gaussian process models (GPs) are a class of supervised machine learning based
on Bayes theory for updating probabilities on the assumed hypotheses. Like SVM approaches, GPs are kernel-based, which makes them efficient for high-dimensional data
analysis. The Gaussian process as implemented here is a probabilistic approach that uses
the average predictive probability instead of a single model. This probabilistic approach
can be adapted to the classification problem by transforming the output using the appropriate activation function [122]. The primary goal for training data points 𝑥𝑖 for 𝑁
samples with an associated binary class labeled as 𝑦𝑖 ∈ {−1, +1}, is to predict the class
for which the new testing data points belong. The basic aim of GP classifiers is to predict
the probabilities of 𝑝(𝑦|𝑥) for the test input. With the following four steps described in
Equations (4.3.1) through (4.3.4), we illustrate how to calculate the GP prediction [47].
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4.3.1

GP Likelihood

The first step in GP prediction is to define a likelihood for the prediction output. Here,
for a binary classification, 𝑦 ∈ {−1, 1}, the probability can be described by a conditional
distribution as follows:

𝑝(𝑦|𝑧) = (1 + 𝑒 −𝑦𝑧 ) −1 = 𝜎(𝑦𝑧)

(4.1)

where 𝜎(•) is the logistic sigmoid function presented in Figure 4.2. As can be seen in
this distribution, in each label, the probability can be controlled by the magnitude of the
𝑧. The GP considers 𝑧 as an unobservable variable. The data likelihood can be defined by
taking the product over all the classes in the training data as expressed in Equation (4.2)
1

p(y|z)

0.8

0.6

y=1
y=-1

0.4

0.2

0
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Figure 4.2: The logistic sigmoid function used in the proposed GP learning is plotted
based on the latent variable 𝑧 and class labels of 𝑦.

𝑝(𝑦|𝑧) =

𝑁
Ö

𝑝(𝑦𝑖 |𝑧𝑖 ) =

𝑖=1

𝑁
Ö
𝑖=1

where 𝑁 is the number of training data.
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𝜎(𝑦𝑖 𝑧𝑖 )

(4.2)

4.3.2

GP Prior

The importance of the specification of GP prior is because of its ability to fix the
properties of the functions for the inference. In order to use the specification of GP prior,
it is assumed that the unobservable variables, [𝑧1 , . . . , 𝑧 𝑁 ] 𝑇 = 𝑧 ∈ 𝑅 𝑁 , are distributed
based on a GP prior, 𝑔(𝑧|0, 𝐾), where

𝑃(𝑧|𝑋) = 𝑔(𝑧|0, 𝐾) =

𝑒𝑥 𝑝(− 12 𝑧𝑇 𝐾 −1 𝑧)
{det(2𝜋𝐾)}1/2

(4.3)

Here, 𝑋 is the training input which is the output of feature selection that may contain
any of the features of MRI, PET, age, education, with 𝑔 being the probability density
function with zero mean vector and its covariance matrix, 𝐾 ∈ 𝑅 𝑁×𝑁 , is symmetric
positive-semidefinite with 𝐾 −1 defining the inverse of the covariance matrix. In order to
obtain the covariance function of the GP prior, we used Gaussian kernel also known as
radial basis function (RBF) that can be computed by Equation (4.4) as follows [121]:

[𝐾] 𝑚,𝑛 = 𝑘 (𝑥 𝑚 , 𝑥 𝑛 ) = 𝑒𝑥 𝑝(−

k (𝑥 𝑚 − 𝑥 𝑛 ) k 2
)
2𝜎 2

(4.4)

where [𝐾] 𝑚𝑛 denotes the element belongs to row 𝑚 and column 𝑛 of the covariance
matrix 𝐾, 𝑘 is the covariance kernel, and 𝑥 𝑚 and 𝑥 𝑛 are the input vectors that can be
represented by RBF kernel as feature vectors.

4.3.3

Marginal likelihood

After obtaining the GP likelihood, 𝑝(𝑦|𝑧), and the GP prior, 𝑃(𝑧|𝑋) = 𝑔(𝑧|0, 𝐾), the
complete data likelihood can be defined as

𝑝(𝑦, 𝑧|𝑋) = 𝑝(𝑦|𝑧) 𝑝(𝑧|𝑋) = 𝑔(𝑧|0, 𝐾)

𝑁
Ö
𝑖=1
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𝜎(𝑦𝑖 𝑧𝑖 )

(4.5)

Considering the fact that 𝑧 is latent, and in order to obtain the marginal likelihood,
equation 4.5 should be integrated with respect to 𝑧 as expressed below:
∫
𝑝(𝑦|𝑋) =

∫
𝑝(𝑦, 𝑧|𝑋)𝑑𝑧 =

𝑔(𝑧|0, 𝐾)

𝑁
Ö

𝜎(𝑦𝑖 𝑧𝑖 )𝑑𝑧

(4.6)

𝑖=1

The marginal likelihood value can thus be interpreted as the probability of observing
the behavior of the training data based on the modeling assumptions.

4.3.4

Posterior distribution

Obtaining the marginal likelihood and the GP prior were the initial steps to obtain the
posterior distribution or the predictions for the test set, 𝑋 0. This distribution is computed
using the following equation
𝑝( 𝑦ˆ0 |𝑋 0)

∫
=

𝑝( 𝑦ˆ0 |𝑧0) 𝑝(𝑧0 |𝑧) 𝑝(𝑧|𝑋)𝑑𝑧𝑑𝑧0

(4.7)

where 𝑝( 𝑦ˆ0 |𝑧0) = 𝜎( 𝑦ˆ0 𝑧0) and the probabilities 𝑝(𝑧|𝑋) and 𝑝(𝑧0 |𝑧) are as defined
𝑝(𝑧|𝑋) =

𝑝(𝑦, 𝑧|𝑋)
𝑝(𝑦|𝑋)

𝑝(𝑧0 |𝑧) = 𝑔(𝑧0 |𝜎0 𝐾 −1 𝑧, 𝜎00 − 𝜎0𝑇 𝐾 −1 𝜎0)

(4.8)

(4.9)

Here, 𝜎00 = 𝐾 (𝑋 0, 𝑋 0) and 𝜎0 = 𝐾 (𝑋 0, 𝑋). In order to solve for Equation (4.5) and
Equation (4.8), we used Laplace approximation for determining a Gaussian approximation
[123]. Having found the posterior distribution, 𝑝( 𝑦ˆ0 |𝑋 0), for prediction as well to examine
the accuracy of the model. In a binary classification, Equation (4.10) is used to make
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a binary prediction. In a binary classification, to make a binary prediction 𝑦ˆ0 ∈ {−1, 1}
based on the posterior distribution as follows:


 +1 if 𝑝( 𝑦ˆ0 = 1|𝑋) > 𝜂,

𝑦ˆ0 =
(4.10)

 −1
otherwise

where 𝜂 ∈ (0, 1) is a coefficient used to compensate the class imbalances in the training
data which is to equal to 0.5 here. For example, if we wish to make fewer false positive
or false negative misclassifications, the threshold parameter, 𝜂, can be tuned in between 0
and 1.

4.4

Results

The feature selection process and the Gaussian model were implemented using R
software [124] to classify 6 binary groups of [CN vs. EMCI, CN vs. LMCI, CN vs. AD,
EMCI vs. LMCI, EMCI vs. AD, and LMCI vs. AD]. Different metrics such as accuracy
(Acc), sensitivity (Sen), and specificity (Spe) are determined to assess the performance
of the algorithm. Table 4.1 presents the classification results using the different imaging
modalities when used separately and when combined. Here, MRI and PET features are
selected based on the proposed feature selection algorithm. As can be seen from the
results, for the most challenging CN vs. EMCI classification, an accuracy of 78.8%, a
sensitivity of 81.4% and a specificity of 76.8% have been obtained when combining MRI,
PET, and the demographic information. It should be noted that sensitivity is viewed as the
most important metric among these parameters since it reflects the accuracy of diagnosing
the true positive group in every binary classification. The EMCI (when considered) is
assumed as true positive, 𝑦 = +1, in every pairwise classification. In other pairs, except
for CN vs. AD, LMCI is considered as the true positive group.
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Table 4.1: Performance comparison of the proposed method for 6 binary groups
Modality
MRI
PET
MRI+PET
MRI+PET+DI**
Modality
MRI
PET
MRI+PET
MRI+PET+DI**
* -:

CN vs. EMCI
CN vs. LMCI
Acc Sen Spe Acc Sen Spe
75.9 77.9 75.5 62.1 48.1 77.5
-*
76.1 66.4 85.8
75.9 77.9 75.5 78.1 69.9 87.8
78.8 81.3 76.8 79.8 70.2 89.9
EMCI vs. LMCI
EMCI vs. AD
Acc Sen Spe Acc Sen Spe
72.1 80.3 61.9 85.6 88.8 87.4
62.8 61.5 64.3 69.1 80.3 45.7
72.5 81.2 66.9 88.1 92.8 87.4
73.2 81.2 69.9 88.1 92.8 87.4

CN vs. AD
Acc Sen Spe
83.6 80.6 85.7
90.0 90.3 89.8
92.5 92.3 93.8
94.7 92.3 95.9
LMCI vs. AD
Acc Sen Spe
62.3 55.3 73.0
69.7 76.0 61.3
77.1 79.9 75.9
77.1 79.9 75.9

No PET features were selected by the RF-RFE process
Demographic information consists of age and education

** DI:

In EMCI vs. CN classification, none of the PET features were selected by the proposed
RF-RFE process, which may indicate that in this early stage SUVR measurements do not
contribute to the classification results. This last assertion indicates that given the low resolution of PET, SUVR measurements are unable to extract the subtle changes that delineate
the two groups of CN and EMCI. Except for the CN vs. EMCI classification, combining
MRI and PET modalities enhanced all accuracy, sensitivity, and specificity results. Inclusion of age and education level to the multimodal (MRI and PET combination) imaging
framework improved the results even further albeit slightly in some cases. Interestingly,
from these results, we see that age and education level did not play any significant role in
the classification of either EMCI and LMCI groups with AD. Based on our finding in this
study, PET features begin to contribute to the overall classification accuracy for the LMCI
group. Figure 4.3 shows classification results including Acc, Sen, Spe, the area under the
curve (AUC), positive predictive value (PPV), and negative predictive value (NPV) for
different modalities separately and combined.
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Figure 4.3: Classification results with 95% confidence interval for different modalities for
the binary classifications of (a) CN vs. EMCI, (b) CN vs. LMCI, (c) CN vs. AD, (d)
EMCI vs. LMCI, (e) EMCI vs. AD, and (f) LMCI vs. AD based on results of Table 4.1.
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Figure 4.4 displays the ROC for the pairwise classification of all the considered groups.
The area under the plot of ROC (AUC), a plot of true positive rate versus false positive rate,
can be a useful tool to evaluate the accuracy of the classifier. An AUC value is between
0 and 1, and an ideal classifier will associate a value of 1. Here, a high AUC of 0.84
was achieved for the challenging CN vs. EMCI classification as mentioned in Figure 4.4.
Evidently, and as expected, higher AUC values of 0.98 for the CN vs. AD classification,
and of 0.95 for the EMCI vs. AD have been achieved. In addition, AUC of 0.77, 0.82,
and 0.83 have been obtained for EMCI vs. LMCI, CN vs. LMCI, and LMCI vs. AD,
respectively. An observation that can be made here is that the AUC value for the EMCI
vs. LMCI is lower than its counterpart for the CN vs. EMCI classification, which could
mean that the neuropsychological test scores used at baseline for this type of delineation
(EMCI vs. LMCI) are more relevant than what neuroimaging measures could extract.
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Figure 4.4: Receiver Operating Characteristics (ROC) curve and Area Under the Curve
(AUC).
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We also investigated what constituted the most important variables which are to be
selected for training the classifier. Table 4.2 provides the eight most important features
selected by the algorithm along with the P-value related to the analysis of variance. Table
4.2 only provides the eight most important features; however, the number of features
that have been selected by the feature selection algorithm is higher for every binary
classification group and could be different from the others. The P-values are produced
in the first step before applying random forest. It can be observed that different features
from MRI and PET data have been selected for the different binary classifications. For
example, all features selected, for the CN vs. EMCI classification belonged to the MRI
data, while most of the features for the binary classifications of CN vs. LMCI and CN vs.
AD were selected from PET data.
Table 4.2: The first eight most important features selected by the feature selection along
with the P-value. (lh: left hemisphere, rh: right hemisphere)
CN vs. EMCI
age
lh lateral ventricle volume
lh precuneus volume
lh superior parietal volume
lh superior frontal volume
rh lingual volume
rh lateral ventricle volume
3rd ventricle volume

P-Value
6.06𝑒−5
3.66𝑒−6
7.24𝑒−5
7.87𝑒−6
1.96𝑒−8
1.46𝑒−6
8.55𝑒−5
2.31𝑒−6

CN vs. LMCI
lh superior frontal SUVR
lh cortical SUVR
lh frontal pole SUVR
rh cortical SUVR
rh superior frontal SUVR
lh parstraingularis SUVR
lh middle temporal SUVR
lh inferior parietal SUVR

P-Value
2.03𝑒−14
1.47𝑒−14
1.76𝑒−12
2.73𝑒−12
1.12𝑒−14
1.87𝑒−14
1.77𝑒−12
3.35𝑒−11

CN vs. AD
lh entorhinal thickness
rh superior frontal SUVR
lh cortical SUVR
rh medial orbitofrontal SUVR
lh rostral middle frontal SUVR
rh frontal pole SUVR
lh caudal middle frontal SUVR
lh accumbens SUVR

P-Value
1.3𝑒−30
9.49𝑒−29
1.25𝑒−29
4.50𝑒−27
6.27𝑒−32
4.30𝑒−30
1.69𝑒−29
1.44𝑒−29

EMCI vs. LMCI
lh precuneus volume
lh superior frontal SUVR
lh cortical SUVR
lh hippocampus volume
lh amygdala volume
lh frontal pole SUVR
lh parahippocampal volume

P-Value
1.45𝑒−4
9.96𝑒−6
4.63𝑒−6
3.90𝑒−8
1.26𝑒−6
1.69𝑒−4
2.82𝑒−4

EMCI vs. AD
lh middle temporal volume
lh middle temporal SUVR
rh middle temporal SUVR
lh entorhinal thickness
rh medial orbitofrontal SUVR
lh hippocampus volume
rh precauneus volume

P-Value
2.50𝑒−18
4.49𝑒−17
1.10𝑒−20
3.02𝑒−25
7.92𝑒−20
1.07𝑒−22
3.16𝑒−14

LMCI vs. AD
rh inferior temporal volume
rh lateral occipital SUVR
lh amyddala volume
lh pericalcarine SUVR
lh hippocampus volume
lh inferior temporal volume
rh pericalcarine SUVR

P-Value
4.05𝑒−6
2.70𝑒−5
1.28𝑒−7
1.58𝑒−6
3.22𝑒−7
1.69𝑒−5
9.80𝑒−6
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We observed that using multimodal imaging enhances the accuracy differently for each
binary classification as a function of the features that were deemed important and from
which modality they were extracted from. The results of CN vs. EMCI and CN vs. LMCI
suggest that the beta-amyloid deposition in its very early stage of Alzheimer’s disease is
not as significant as in the later stage of the disease. The amyloid burden will probably
continue to increase during the transition between EMCI and LMCI. Figure 4.5 shows
the importance of the features based on the Gini importance measure which are listed in
Table 4.2 for the challenging group, CN vs. EMCI. In addition, Figure 4.6 presents box
plot of different features from CN vs. EMCI, CN vs. LMCI, and CN vs. AD classifications, indicating the significance of different features at the different stages of the disease.

age
lh lateral ventricle volume
lh precuneus volume
lh superior parietal volume
lh superior frontal volume
rh lingual volume
rh lateral ventricle volume
3rd ventricle volume

0.5 0.52 0.54 0.56 0.58 0.6 0.62 0.64 0.66 0.68 0.7

Importance

Figure 4.5: Importance of the features listed in Table 4.2 for the most challenging CN vs.
EMCI classification.
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Figure 4.6: Boxplot of different features for (a)-(d): CN vs. EMCI, (e)-(h): CN vs. LMCI,
and (i)-(l): CN vs. AD.
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To assess the performance of the proposed method, we compared our results with the
SVM classifier using the same kernel and the same features. The results as provided in Table 4.3, indicate that GP with linear kernel does not provide higher accuracy in comparison
to the GP with RBF in most groups except for CN vs. LMCI. GP with the linear kernel is
more successful to detect LMCI in group of CN vs. LMCI; however, the computation time
for this method is significantly higher than the other methods as can be seen from Table 4.4.

Table 4.3: Performance Comparison of the Gaussian classifier with SVM using the same
kernel and the same feature including the MRI, PET, and DI. (RBF: radial basis function
kernel, and L-K: linear kernel)
CN vs. EMCI
Acc Sen Spe
SVM (RBF-K) 75.6 78.9 70.6
GP (RBF-K)
78.8 81.3 76.8
SVM (L-K)
69.4 71.2 67.4
GP (L-K)
68.7 67.7 75.0
EMCI vs. LMCI
Acc Sen Spe
SVM (RBF-K) 70.1 80.0 60.0
GP (RBF-K)
73.2 81.2 69.9
SVM (L-K)
72.1 79.1 68.3
GP (L-K)
72.0 78.3 67.9

CN vs. LMCI
Acc Sen Spe
76.9 69.3 85.7
79.8 70.2 89.9
78.7 70.6 82.8
81.5 76.3 86.6
EMCI vs. AD
Acc Sen Spe
85.5 90.5 80.8
88.1 92.8 87.4
79.2 84.8 67.8
81.4 81.0 83.1

CN vs. AD
Acc Sen Spe
91.2 90.1 93.9
94.7 92.3 95.9
92.6 89.4 93.7
91.5 91.3 92.7
LMCI vs. AD
Acc Sen Spe
75.3 73.3 75.6
77.1 79.9 75.9
80.2 80.1 80.7
70.7 70.9 73.8

Table 4.4: Computation time in second for SVM and GP using linear and RBF kernels
(Variables are represented in seconds)
CN vs. EMCI
SVM (RBF-K) 96.58
GP (RBF-K)
44.48
SVM (L-K)
15.21
GP (L-K)
2453.97
EMCI vs. LMCI
SVM (RBF-K) 90.12
GP (RBF-K)
38.22
SVM (L-K)
15.77
GP (L-K)
1756.32
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CN vs. LMCI
74.52
28.8
11.21
4963.02
EMCI vs. AD
67.69
27.6
19.62
1833.21

CN vs. AD
61.22
18.3
22.08
915.47
LMCI vs. AD
62.88
25.18
10.62
729.53

In order to assess the performance of the proposed method, the classification results of
some well-established feature selection methods using SVM and GP classifiers for 3 binary
classifications of CN vs. EMCI, CN vs. LMCI, and CN vs. AD are plotted in Figure 4.7.
Combination of t-test with GP classifier and random forest recursive feature elimination
feature selection with GP and SVM classifiers have higher accuracy in comparison to the
other combination algorithms.

4.5

Discussion

In this study, we evaluated a machine learning algorithm based on the Gaussian process for the delineation of the challenging EMCI from the CN group. The similarity of
the SVM and Gaussian process is in using the covariance kernel; however, the maximum
margin approach is distinct in the SVM approach. The classification results of GP and
SVM are not statistically significant; however, GP provides the predicted probability of
the labels which could be beneficial in the clinical investigation while SVM provides the
binary predicted labels. For example, the small predicted probability for a subject will
suggest more tests are required in a clinical setting. Moreover, temporal atrophy seems
to be more relevant for the CN vs. LMCI binary classification rather than for the more
challenging CN vs. EMCI. This indicates that memory deterioration of the medial temporal lobe mostly occurs at the transition from EMCI to the LMCI stage. In addition, we
observed that the most important variables are often selected from the left hemisphere of
the brain may suggest that more deterioration has taken place on the left hemisphere than
the right hemisphere more, specifically in the transition from EMCI to LMCI although the
right/left-handed information of the participants is not available to make a strong statement.
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Figure 4.7: Classification results with 95% confidence interval for combination of different
feature selection using SVM and GP classifiers for the most important classifications of
(a) CN vs. EMCI, (b) CN vs. LMCI, and (c) CN vs. AD. (MRMR: minimum redundancy
maximum relevance, RF-RFE: random forest recursive feature elimination)
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So far, only a limited number of studies have considered EMCI and LMCI groups
[8, 53–56, 58, 59, 61]. Table 4.5 lists all the classification results from previous studies
which are compared to the proposed method. One advantage of the proposed method over
the previously reported methods is that the results offer both higher accuracy and higher
sensitivity values for most classification groups although the confidence intervals have not
been considered in those studies for full comparison purposes.

Table 4.5: Accuracy (Acc), sensitivity (Sen), and specificity (Spe) of the Gaussian classifier comparing to the previous works. (dMRI: diffusion magnetic resonance imaging,
fMRI: functional magnetic resonance imaging, and DI: demographic information)

[59]
[53]
[56]
[61]
[58]
proposed

[59]
[53]
[56]
[61]
[58]
proposed

CN vs. EMCI
Modality
Acc Sen Spe
MRI
56 52 60
dMRI
59.2 MRI
65 61 69
fMRI
66.0 71.4 64.1
fMRI
72.8 78.3 67.1
MRI+PET+DI 78.8 81.3 76.8
EMCI vs. LMCI
Modality
Acc Sen Spe
MRI
63 62 66
dMRI
63.4 MRI
fMRI
fMRI
MRI+PET+DI 73.2 81.2 69.9
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CN vs. LMCI
Acc Sen Spe
59 52 64
62.8 78.6 82.5 72.2
79.8 70.2 89.9
EMCI vs. AD
Acc Sen Spe
81 70
82
88.1 92.8 87.4

CN vs. AD
Acc Sen Spe
84 73 89
78.2 86 86 85
93.8 92.8 95.7
88.9 91.7 85.7
94.7 92.3 95.9
LMCI vs. AD
Acc Sen Spe
67 58 73
77.1 79.9 75.9

CHAPTER 5
PREDICTION OF CONVERSION FROM NORMAL COGNITION AND MILD
COGNITIVE IMPAIRMENT TO ALZHEIMER’S DISEASE

5.1

Goal

This study aims to examine disease progression in the early stage using longitudinal
data. Longitudinal analysis of multimodal neuroimaging data is essential for understanding Alzheimer’s disease and its progression as a function of the different risk factors.
Predication of progression from mild cognitive impairment (MCI) to AD is widely investigated; however, the conversion from cognitively normal (CN) to MCI and on to AD is
largely unexplored. Identification of individuals with normal cognition that are likely to
progress to MCI or AD over time will improve the planning and efficacy of any treatment
in clinical trials. Therefore, we investigated conversion from both groups of CN and MCI
by predicting cognitive tests including Alzheimer’s disease assessment scale cognitive
subscale (ADAS-Cog), Mini-mental state examination (MMSE), and Rey’s auditory verbal learning (RAVLT) that have been designed and used as important criteria to evaluate
the cognitive status of patients. In this study, we formulated the prediction of disease progression as a multitask regression problem by considering a task as the prediction of the
cognitive score at each time point and multiple prediction tasks across all available time
points simultaneously to capture the temporal smoothness of the model through an undirected dependency graph for all tasks. The proposed model learns subject’s trajectories of
Magnetic Resonance Imaging (MRI) features, Cerebrospinal fluid (CSF), Fluorodeoxyglucose (FDG)-PET, and Apolipoprotein E (APOE) gene with a multitask approach for every
single modality and fuse the results to predict the aforementioned neuropsychological tests
in a longitudinal study with a 4-year duration. In addition, we investigated the association
between brain structural patterns changes in disease progression and observed that white
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matter volume of the left hippocampus, cortical thickness average of left middle temporal,
and right entorhinal play significant roles in predicting the cognitive scores. We also
observed alternations within the insula in the conversion from MCI and normal cognition
to AD.

5.2
5.2.1

Material and Methods
Participants and Data Acquisition

Data used in the preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database. The multimodal data in this study used
longitudinal information from 779 subjects in a 4-year time window which were categorized into 3 groups: cognitively normal (CN), mild cognitive impairment (MCI), and
Alzheimer’s disease (AD) at baseline (BL or T1). These subjects are subsequently divided into 5 categories of CN stable (CNs), CN converter (CNc), MCI stable (MCIs),
MCI converter (MCIc), and AD in context to the next 5 time points (T6, T12, T24, T36,
and T48), with 6, 12, 36, and 48 being the number of months after baseline. This is
based on the conversion or stability of the subject’s cognition status within the 4-year
duration. In this study, subjects that were diagnosed as CN/MCI at baseline and the status
has not been changed during the 4 years are considered as CN/MCI stable. It should be
mentioned that the subjects are considered converter if they progressed to either MCI or
AD within the 4 years, and are considered as stable even if they eventually converted after
the 4 years. All subjects that have conversions from MCI to CN or from AD to MCI are
excluded in this study. Demographic information of the subjects is provided in Table 5.1.
Among cognitive scores, 4 neuropsychological tests of ADAS, MMSE, and RAVLT including RAVLT immediate (RAVLT-Im) and RAVLT percent forgetting (RAVL-PF) were
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selected for predictive modeling. The demographic information of participants based on
converted groups is also provided in Table 5.2. In addition, evolution patterns of the
different groups categorized in Table 5.2 over the 6 available time points are depicted in
Figure 5.1 which shows average changes of cognitive scores in progression trajectory.

Table 5.1: Participants Demographic information at baseline. Values are represented as
mean (standard deviation)
CN
MCI
AD
Subjects
223
394
162
Age
74.51(5.29) 73.24(7.29) 74.03(7.91)
CDR
0.03(0.13)
1.51(0.83)
4.32(1.66)
MMSE
29.13(1.02) 27.37(1.75) 23.22(2.01)
ADAS
8.94(4.19)
17.42(6.52) 28.41(7.94)
RAVLT-Im 44.99(9.26) 32.66(10.06) 23.22(7.78)
RAVLT-PF 33.32(27.81) 64.08(32.19) 87.67(22.73)

Table 5.2: Participants Demographic information at baseline. Values are represented as
mean (standard deviation)
CNs
CNc
Subjects
203
20
Age
74.32(5.12)
76.95(5.16)
CDR
0.08(0.30)
0.52(1.02)
MMSE
29.13(1.12) 28.47(1.56)
ADAS
8.33(4.10)
12.71(6.10)
RAVLT-Im 44.91(9.92)
38.29(10.10)
RAVLT-PF 32.66(27.14) 47.64(31.49)

5.2.2

MCIs
265
73.16(7.37)
1.46(0.97)
27.58(2.11)
15.67(6.88)
34.38(10.89)
59.60(40.12)

MCIc
AD
129
162
72.94(7.03) 74.03(7.91)
3.36(2.23)
4.32(1.66)
24.77(3.75) 23.22(2.01)
25.28(8.76) 28.41(7.94)
24.08(7.90) 23.22(7.78)
83.74(39.21) 87.67(22.73)

Cognitive tests

MMSE is one of the most well-known tests that was designed to monitor the development of overall cognitive impairment [125]. The scale of this score is 0 to 30 which 20 to
24 is considered mild dementia, 13 to 20 indicates moderate dementia, and less than 12
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Figure 5.1: Average changes of cognitive scores for the 5 different groups of CNs, CNc,
MCIs, MCIc, and AD across the 6 time points for method for (a) MMSE (b), ADAS (c),
RAVLT-Im, and (d) RAVLT-PF.

suggest severe dementia; however, in many studies, MMSE scores of 0-10, 11-20, 21-25,
26-29, and 30 have been considered as a projection of CDR of 3 or above, 2, 1, 0.5, and 0
indicating severe, moderate, questionable, and normal cognition, respectively [126].

ADAS-cog which can be considered as a gold standard in antidementia treatments was
developed originally for later stages of dementia where cognitive decline is more severe;
however, it is often used in the earlier stage of MCI [127]. The ADAS-11 score includes 11
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tasks that evaluate domains of language, ideational and constructional praxis (assembling
parts into a structure), word recognition, remembering test instructions, speaking, and
language word-finding difficulty. On the other hand, ADAS-13 was designed later with
better performance for disease progression in the early stage, which combines the 11 tasks
of ADAS-11 with a delayed word recall as well as a maze task added. Thus, for practical
purposes, only ADAS-13 was considered here as ADAS test score.

RAVLT is another powerful test to assess verbal learning and episodic memory during
the progression of Alzheimer’s disease. RAVLT procedure is based on repeated tasks of
presenting 15 words in consecutive trials for the subjects and ask them to recall as many
words as they can remember for those tasks at each trial [128].

5.2.3

Neuroimaging

In this study multimodal neuroimaging of MRI, FDG-PET, and CSF along with APOE
𝜀4 allele were used. The number of MRI measurements are 319 including 275 cortical
features (left/right white matter volume, cortical volume, surface area, cortical thickness,
and standard deviation of thickness plus total intracranial volume (ICV)) and 44 subcortical features including left/right subcortical volumes of subcortical brain regions. The
FDG-PET biomarkers determine the metabolic changes in the brain. CSF biomarker
includes 3 features of phosphorylated tau protein (p-Tau), amyloid-𝛽 (A-𝛽), and total tau
protein (t-Tau). Tau plays an important role in adjusting axonal transport, microtubule
dynamics, and neurite outgrowth which lead to clinical diagnostic settings of Alzheimer’s
disease [129–131]. Finally, APOE 𝜀4 allele is responsible for carrying lipids through the
bloodstream which is considered as a major genetic risk factor for AD [132, 133]. On the
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other hand, as mentioned before all subjects have measurements at the baseline or T1 but
may not have all neuroimaging measures for the next five time points of T6, T12, T24,
T36, and T48. Table 5.3 Shows the number of observations for the different modalities
at different time points. We can see from Table 5.3 the extent of missing data especially
and expectedly for the PET and CSF, which highlights the importance and necessity of
managing the missing values.

Table 5.3: Number of observations for different modalities at different time points of
T1-T48
Modality
MRI
PET
CSF
APOE

5.2.4

T1
779
521
501
779

T6
695
209
4
695

T12
654
194
181
654

T24
503
286
143
503

T36
238
81
35
238

T48
144
46
50
144

Fused Gaussian Sparse Group Lasso (FGSGL)

In longitudinal study of Alzheimer’s disease, predicting the cognitive scores at any
time point is a regression problem that can be developed as a multitask regression problem
by predicting multiple tests or predicting a test at multiple time points. In this study a
multitask learning approach has been applied for the prediction of any of the considered
cognitive scores for all time points T1 through T48. Let us consider the input matrix as 𝑋𝑡 =
{𝑥 1 , 𝑥 2 , ..., 𝑥 𝑁 } and target matrix or neuropsychological test score as 𝑦 𝑡 = {𝑦 1 , 𝑦 2 , ..., 𝑦 𝑁 },
therefore, 𝑋𝑡 ∈ 𝑅 𝑁×𝐹 and 𝑦 𝑡 ∈ 𝑅 𝑁 where 𝑁 is the number of observations and 𝐹 is the
number of features of neuroimaging at the time of 𝑡 = 1, 2, . . . , 𝑇. It should be noted
that all vectors are defined with lowercase letters, and matrices are defined with uppercase
letters throughout this article. If the regression parameters across all tasks are considered
as Φ ∈ 𝑅 𝐹×𝑇 matrix, then 𝜑 ∈ 𝑅 𝐹 denotes the column of regression parameters of the task
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at the time 𝑡. 𝑊𝑡 = {𝑤 1 , 𝑤 2 , ..., 𝑤𝑇 } is the weight matrix at all time points. A kernel-based
smoothing approach [134] which is used to local smoothing in order to minimize the
regression error at each time point is associated with the task 𝑡 and neighbor 𝜑𝑡 . Thus, the
approximation model can be determined as below:

𝜑ˆ𝑡 =

𝑇
∑︁

𝑤 𝑟,𝑡 𝜑𝑟 ,

𝑡 = 1, 2, ..., 𝑇

(5.1)

𝑟=1
𝑟≠𝑡

where 𝑤 𝑟,𝑡 =

𝐾 ( 𝑟𝜎−𝑡 )
Í𝑇
𝑟 −𝑡 ,
𝑟=1 𝐾 ( 𝜎 )
𝑟≠𝑡

𝑟 = 1, 2, ..., 𝑇, 𝑟 ≠ 𝑡

Here 𝜎 is the bandwidth and 𝐾 is the kernel matrix using the Gaussian kernel as
2
𝑎2
𝐾 = √ 𝑒𝑥 𝑝( )
2
2𝜋

(5.2)

In Equation (5.1), the weights are defined by the Gaussian kernel where its bandwidth
needs to be determined. A small value of 𝜎 leads to quick decay of the Gaussian curve,
and vice versa the larger value is to allow for the curve to decay gradually. We determined
𝜎 = 14 as an appropriate empirical value to be used in this study.

On the other hand, the fused aspect of the model is obtained by adding sparsity on the
matrix of residuals [135]. The fused penalty or the transformation matrix as used in this
study can be defined as 𝐺 ∈ 𝑅 (𝑇×𝑇) in the term of 𝑃 = Φ𝐺 as follow

h

𝜌1 𝜌2 · · ·

i
𝜌𝑇

h
= 𝜑1 𝜑2 · · ·


.
 𝐼
−𝑤 |𝑡−𝑟 | 𝐼 −𝑤 |𝑡−𝑟 | 𝐼 ..


..
..
i −𝑤 |𝑡−𝑟 | 𝐼
𝐼
.
.

𝜑𝑇 
..
..
..
..
.
.
.
.



−𝑤 |𝑡−𝑟 | 𝐼 −𝑤 |𝑡−𝑟 | 𝐼 −𝑤 |𝑡−𝑟 | 𝐼 · · ·



−𝑤 |𝑡−𝑟 | 


−𝑤 |𝑡−𝑟 | 𝐼 

..

.



𝐼 

(5.3)
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The matrix of 𝐺 includes the weights 𝑤 𝑡,𝑟 = 𝑤 |𝑡−𝑟 | demonstrating the edges between
the nodes 𝑡 and 𝑟. Therefore, the solution for the multitask problem is to solve the following
unconstrained optimization equation:

𝑚𝑖𝑛

𝑇
∑︁

Φ,𝑃

||𝑦 𝑡 − 𝑋𝑡 𝜑𝑡 || 2 + 𝐻 𝛽2 (Φ) + 𝛽3 ||𝑃|| 1 ,
𝛽1

𝜌𝑡 = 𝜑𝑡 −

𝑇
∑︁

𝑤 𝑟,𝑡 𝜑𝑟

(5.4)

𝑟=1
𝑟≠𝑡

𝑡=1

where the columns of residuals 𝜌𝑡 creates the matrix of residuals 𝑃 ∈ 𝑅 𝐹×𝑇 , the 𝛽1,
𝛽1

𝛽2, and 𝛽3 are the regularization parameters, and 𝐻 𝛽2 (Φ) = 𝛽1 ||(Φ)|| 1 + 𝛽2 ||(Φ)|| 2,1
denotes the combination of penalties of the lasso and the group lasso. The group lasso
Í𝐹
defined as ||(𝜑)|| 2,1 = 𝑖=1
||𝜑𝑖 || considers the groups across all time points for each
variable 𝑖, which allows sharing a common set of variables at each time point.

In the next step, an alternating direction method of multiplier (ADMM) is used to solve
the unconstrained optimization problem in Equation (5.4) which is difficult to be optimized
directly. To this purpose consider the formulation as a linear constrained optimization
problem as follow

𝑚𝑖𝑛

𝑇
∑︁
1

Φ,𝑃,Γ,Θ
𝑡=1

2

||𝑦 𝑡 − 𝑋𝑡 𝜑𝑡 || 2 + 𝐻 𝛽2 (Θ) + 𝛽3 ||Γ|| 1
𝛽1

(5.5)

here Θ and Γ are the feasible sets where Φ − Θ = 0, 𝑃 − Γ = 0, and the column of
Í
residuals in the feasible set is defined as 𝜌𝑡 = 𝜑𝑡 − 𝑇𝑟=1 𝑤 𝑟,𝑡 𝜑𝑟 .
𝑟≠𝑡

The augmented Lagrangian can be determined as follows:
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𝐿 𝛿 (Φ, 𝑃, Θ, Γ, 𝐴, 𝑀, 𝑁) =

𝑇
∑︁
1
𝑡=1

𝛿
+ ||Φ − Θ|| 2 +
2

𝑇
∑︁
𝑡=1

{𝜇𝑇𝑡 (𝜑𝑡 −

2

||𝑦 𝑡 − 𝑋𝑡 𝜑𝑡 || 2 + 𝐻 𝛽2 (Θ) + 𝛽3 ||Γ|| 1 + 𝑡𝑟 ( 𝐴𝑇 (Φ − Θ)

𝑇
∑︁

𝛽1

𝑤 |𝑡−𝑟 | 𝜑𝑟 − 𝜌𝑡 ) +

𝑟=1
𝑟≠𝑡

𝑇
𝑇
∑︁
𝛿 ∑︁
||𝜑𝑡 −
𝑤 |𝑡−𝑟 | 𝜑𝑟 − 𝜌𝑡 )|| 2 }
2 𝑡=1
𝑟=1
𝑟≠𝑡

𝛿
+𝑡𝑟 (𝑁 𝑇 (𝑃 − Γ)) + ||𝑃 − Γ|| 2
2
(5.6)
where 𝐴, 𝑀, 𝑁 ∈ 𝑅 𝐹×𝑇 are Lagrangian multipliers associated with Φ − Θ = 0,
Í
𝜑𝑡 − 𝑇𝑟=1 𝑤 |𝑡−𝑟 | 𝜑𝑟 − 𝜌𝑡 = 0, and 𝑃 − Γ = 0 constraints, including the vectors of 𝛼, 𝜇,
𝑟≠𝑡

and 𝜈, respectively. In addition, 𝑡𝑟 (.) shows the trace of a matrix and 𝛿 is the penalty
parameter which is used to define the dual ascent step size in ADMM [136].

If we define Φ(𝑞) as in Equation (5.7) and considering 𝑞 𝑡𝑘 as the gradient with respect
to 𝜑𝑡 , then the regression parameter matrix can be calculated through using Algorithm 1
as follow:

𝑇
𝑇
∑︁
𝛿 ∑︁
𝑤 |𝑡−𝑟 | 𝜑𝑟 − 𝜌𝑡 )|| 2
||𝜑𝑡 −
𝑞(Φ) =
2 𝑡=1
𝑟=1

(5.7)

𝑟≠𝑡

Finally, the regression matrix Φ is obtained with 𝑁 number of observation at 𝑡 = 𝑇
time point samples. Therefore, 𝑀 modality-specific regression matrices generate the 𝑀
𝑡 × Φ𝑡 .
primary prediction of each cognitive score of 𝑦ˆ using 𝑦ˆ 𝑡𝑀 = 𝑋 𝑀
𝑀
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Algorithm 1: Steps to update primal and dual variables for ADMM
• Determine the initial variables of 𝐴 𝑘 , 𝑀 𝑘 , 𝑁 𝑘 , Θ 𝑘 , Γ 𝑘 , 𝑃 𝑘 , and Φ 𝑘
• Repeat the following steps until termination criterion is satisfied
– 𝜑𝑡𝑘+1 ← 𝑎𝑟𝑔𝑚𝑖𝑛 2𝛿 ||𝑦 𝑡 − 𝑋𝑡 𝜑𝑡 || 2 + (𝛼𝑡𝑘 )𝑇 𝜑𝑡 + 2𝛿 ||𝜑𝑡 − 𝜃 𝑡𝑘 || 2 + (𝜇𝑡𝑘 + 𝑞 𝑡𝑘 )𝑇 𝜑𝑡 +
𝛿1
2 ||𝜑𝑡

−

𝜑𝑡
𝑘
2
𝜑𝑡 ||

– 𝜌𝑡𝑘+1 ← 𝑎𝑟𝑔𝑚𝑖𝑛 2𝛿 ||𝜌𝑡 − {𝛾𝑡𝑘 + 𝜑𝑡𝑘+1 −
𝜌𝑡

Í𝑇
𝑟=1
𝑟≠𝑡

𝑤 |𝑡−𝑟 | 𝜑𝑟𝑘+1 }|| 2 − (𝜇𝑡𝑘 + 𝜈𝑡𝑘 )𝑇 𝜌𝑡

– Θ 𝑘+1 ← 𝑠𝑖𝑔𝑛(Φ 𝑘+1 + 1𝛿 𝐴 𝑘 ) 𝑚𝑎𝑥(|Φ 𝑘+1 + 1𝛿 𝐴 𝑘 | −
– Θ 𝑘+1 ←

𝛽1
𝛿 , 0)

𝑚𝑎𝑥{||Θ 𝑘+1 || 2 − 𝛽2
𝛿 ,0}
||Θ 𝑘+1 || 2

– Γ 𝑘+1 ← 𝑠𝑖𝑔𝑛(𝑃 𝑘+1 + 1𝛿 𝑁 𝑘 ) 𝑚𝑎𝑥(|𝑃 𝑘+1 + 1𝛿 𝑁 𝑘 | −
– 𝐴 𝑘+1 ← 𝐴 𝑘 + 𝛿(Φ 𝑘+1 − Θ 𝑘+1 )
– 𝜇𝑡𝑘+1 ← 𝜇𝑡𝑘 + 𝛿(𝜑𝑡𝑘+1 −

Í𝑇
𝑟=1
𝑟≠𝑡

𝑤 |𝑡−𝑟 | 𝜑𝑟𝑘+1 − 𝜌𝑡𝑘+1

– 𝑁 𝑘+1 ← 𝑁 𝑘 + 𝛿(𝑃 𝑘+1 − Γ 𝑘+1 )
– 𝐴 𝑘 = 𝐴 𝑘+1 , 𝑁 𝑘 = 𝑁 𝑘+1
– 𝜑𝑡𝑘 = 𝜑𝑡𝑘+1 , 𝜇𝑡𝑘 = 𝜇𝑡𝑘+1 , 𝜃 𝑡𝑘 = 𝜃 𝑡𝑘+1
• Φ←Θ
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𝛽3
𝛿 , 0)

5.2.5

Fusion Algorithm

In the second step, we need to ensemble the primary predictions of specific-modalities
which was calculated using the FGSGL, as described in section 5.2.4, separately. An
ensemble technique is used to combine the predictions from multiple classification or
regression algorithms to make more accurate predictions that could be achieved from any
learning algorithm alone. Here a least-squares boosting (LS-Boost) was used to combines
multiple weak learners into one strong learner in order to fuse the specific-modalities
predictions. The algorithm uses multiple decision tree regressors to train the network
sequentially with respect to residual errors made by the previous regressor. Therefore,
missing data can be handled using the decision trees for training the network as well as
minimizing the error using sequential training. If there would be any missing data, the
algorithm selects a new split with input data which is called surrogate split, that is not to
involve the missing data in the training process.

Here the input matrix is defined as 𝑦ˆ 𝑡 = [ 𝑦ˆ 𝑡1 , 𝑦ˆ 𝑡2 , ..., 𝑦ˆ 𝑡𝑀 ] from the last section. For
simplicity in notation, we consider the input matrix of 𝑋 = [𝑥 1 , 𝑥2 , ..., 𝑥 𝑀 ] ∈ 𝑅 𝑁×1 where
𝑁 is the number of observations and 𝑀 is the number of modalities that are going to be
fused at each time point. Therefore, the response vector of the cognitive score can be
defined as 𝑦 ∈ 𝑅 𝑁×1 . We assume that 𝑋 is normalized to have zero mean and unit 𝑙2-norm
and 𝑦 has also zero mean. Therefore, the estimated response vector is calculated by 𝑋𝜆
with the residuals of 𝑘 = 𝑦 − 𝑋𝜆. The following Algorithm provides the steps to find the
regression coefficient vector of 𝜆 [137].
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Algorithm 2: The two-step algorithm for least square boosting (LS-Boost)
• Fix number of iterations 𝑡 > 1 and the learning rate of 𝛼 > 0
• Determine the initial values as 𝑘ˆ 0 = 𝑦, 𝜆ˆ 0 = 0, and 𝑚 = 0
• For 0 ≤ 𝑚 ≤ 𝑡 repeat the following
– Find the covariates of 𝑗 𝑚 and 𝑢˜
∗ 𝑢˜ ← 𝑎𝑟𝑔𝑚𝑖𝑛 (

ˆ𝑚
𝑖=1 ( 𝑘 𝑖

− 𝑥𝑖𝑟 𝑢) 2 )

ˆ𝑚
𝑖=1 ( 𝑘 𝑖

− 𝑥𝑖𝑟 𝑢)
˜ 2

Í𝑁

𝑓 𝑜𝑟 𝑟 = 1, 2, ..., 𝑀

𝑢∈𝑅

∗ 𝑗 𝑚 ← 𝑎𝑟𝑔𝑚𝑖𝑛

Í𝑁

0≤𝑟 ≤𝑀

– Update the regression coefficients and residuals as
∗ 𝑘ˆ 𝑚+1 ← 𝑘ˆ 𝑚 − 𝛼𝑋 𝑗 𝑚 𝑢˜ 𝑗 𝑚
ˆ𝑚
∗ 𝜆ˆ 𝑚+1
𝑗 𝑚 ← 𝜆 𝑗 𝑚 + 𝛼𝑋 𝑗 𝑚 𝑢˜ 𝑗 𝑚
∗ 𝜆ˆ 𝑚+1
← 𝜆ˆ 𝑚𝑗 ,
𝑗

𝑗 ≠ 𝑗𝑚

The overall view of the two-step proposed framework is shown in Figure 5.2. The
empty boxes in Multitask learning step represent missing values for primary predictions
due to missing input data of PET, CSF, and APOE in comparison to MRI. Since all subjects have MRI but not necessarily PET, CSF, and APOE information, predicted cognitive
scores resulted from those modalities would have missing values.
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Figure 5.2: Overall view of the proposed framework to predict neuropsychological test
𝑗
scores. The portion highlighted in white in the predicted 𝑦ˆ 𝑖 vectors signify the proportion
of missing data.
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5.3

Results

In this study, a 10-fold cross-validation has been used to prevent any bias in the training and testing datasets. The hyperparameters of 𝛽1, 𝛽2, and 𝛽3 for regularization were
selected from 1 to 10. In addition, the optimal number of decision trees in boosting was
selected from 1 to 100. The data has been normalized to have zero mean and unit variance
after splitting the data into training and testing sets. The performance of predicting the
4 cognitive scores of MMSE, ADAS, RAVLT-Im, and RAVLT-PF using multimodal data
including MRI, PET, CSF, and APOE is evaluated in terms of Root Mean Square Error
(RMSE) and correlation coefficient (R2 ) between predicted values and actual values in
the testing phase. The mean and standard deviation of RMSE obtained from each trial are
averaged for 10-fold cross-validation. The final results in terms of RMSE are presented
in Table 5.4. The scatter plots of predicted cognitive scores of MMSE and ADAS versus
actual scores along with the correlation of R2 are shown in Figures 5.3 and 5.4. In addition,
the correlation of 0.68, 0.64, 0.66, 0.67, 0.71, and 0.73 are obtained for the prediction of
RAVLT-Im scores across the 6 time points of T1 through T48, respectively. The correlation of 0.62, 0.67, 0.56, 0.69, 0.61, and 0.70 are also obtained for prediction of RAVLT-PF.

Table 5.4: Prediction performance in terms of RMSE for the 4-year time window based
on multimodal neuroimaging. Values are represented as mean (standard deviation)
Tests
MMSE
ADAS
RAVLT-Im
RAVLT-PF

T1
1.69(0.15)
4.92(0.64)
7.75(0.69)
20.37(4.3)

T6
2.01(0.30)
5.56(0.53)
8.27(0.63)
24.37(5.6)

T12
1.72(0.20)
6.11(0.73)
8.16(0.87)
22.26(1.7)
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T24
1.89(0.17)
5.34(0.59)
7.97(1.24)
21.29(2.5)

T36
1.94(0.29)
5.90(0.91)
8.24(0.94)
25.80(5.5)

T48
1.80(0.61)
6.69(1.13)
7.91(1.60)
23.85(4.8)
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Figure 5.3: Scatter plot of predicted MMSE score vs. actual MMSE score along with the
correlation coefficient at 6 time points. The orange line is regression line and the dotted
gray line is the reference of perfect correlation.

68

Correlation=0.80 at T1

Correlation=0.83 at T6

70

60

60

50

50

Predicted ADAS

Predicted ADAS

70

40

30

40

30

20

20

10

10

0

0
0

10

20

30

40

50

60

70

0

10

20

Actual ADAS

(a)

60

60

50

50

Predicted ADAS

Predicted ADAS

50

60

70

50

60

70

50

60

70

Correlation=0.80 at T24

70

40

30

40

30

20

20

10

10

0

0
0

10

20

30

40

50

60

70

0

10

20

Actual ADAS

30

40

Actual ADAS

(c)

(d)

Correlation=0.83 at T36

70

Correlation=0.83 at T48

70

60

60

50

50

Predicted ADAS

Predicted ADAS

40

(b)

Correlation=0.80 at T12

70

30

Actual ADAS

40

30

40

30

20

20

10

10

0

0
0

10

20

30

40

50

60

70

Actual ADAS

0

10

20

30

40

Actual ADAS

(e)

(f)

Figure 5.4: Scatter plot of predicted ADAS score vs. actual ADAS score along with the
correlation coefficient at 6 time points. The orange line is regression line and the dotted
gray line is the reference of perfect correlation.
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As mentioned before, we considered 5 groups of CNs, CNc, MCIs, MCIc, and AD
for predicting the progression from CN to MCI or AD as well as MCI to AD. Subjects
were grouped as CN converter if they were diagnosed CN at baseline and then converted
to MCI or AD in the next 4 years, but not converting back to CN in that time window. In
the same procedure, subjects were grouped as MCI converter if they were diagnosed as
MCI at baseline and converted to AD but not converting back to CN or MCI within the
next 4 years. In addition, the subjects were considered CNs/MCIs if they were CN/MCI at
baseline and did not convert at any of the next 5 time points even if they convert afterward.
Table 5.5 show RMSE of these five categories separately for all time points.

Table 5.5: Prediction performance of MMSE and ADAS for the 4-year time window based
on multimodal neuroimaging for different groups of subjects separately
MMSE
CNs
CNc
MCIs
MCIc
AD
ADAS
CNs
CNc
MCIs
MCIc
AD

T1
1.48(0.27)
1.95(0.48)
1.79(0.46)
2.71(0.76)
3.10(0.63)
T1
5.12(0.88)
6.14(1.01)
4.70(0.93)
5.87(1.04)
6.12(1.48)

T6
1.38(0.18)
1.87(0.10)
1.75(0.09)
2.47(0.09)
3.07(0.54)
T6
5.47(0.73)
6.16(1.77)
5.45(1.08)
5.72(1.62)
7.60(1.45)

T12
1.37(0.19)
1.32(0.16)
1.98(0.16)
2.77(0.14)
3.32(0.73)
T12
5.66(0.78)
6.07(1.51)
5.65(0.83)
6.35(1.23)
7.95(1.56)

T24
1.38(0.18)
1.33(0.15)
1.97(0.16)
2.93(0.39)
3.35(1.21)
T24
5.00(1.47)
4.07(1.98)
5.67(1.33)
6.80(1.12)
7.54(0.87)

T36
1.18(0.12)
1.54(0.45)
1.73(0.15)
2.04(0.82)
T36
4.63(2.18)
4.52(1.12)
5.36(2.05)
5.85(1.85)
-

T48
1.24(0.32)
1.26(0.88)
1.81(0.23)
2.76(0.76)
T48
4.12(2.38)
5.35(2.26)
4.44(1.08)
6.23(2.05)
-

Figure 5.5 provides a box plot of the distributions of predicted cognitive scores vs.
actual scores for the 5 groups separately and combined. We obtained RMSE of 1.95 for
normal cognition groups who later converted to MCI or AD and RMSE of 2.71 for the
MCI group who converted to AD later during the 4 years.
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Figure 5.5: Box plot of prediction MMSE score vs. actual MMSE score using the test set
based on multimodal neuroimaging for all groups of subjects separately and combined
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Furthermore, Figures 5.6 and 5.7 show the delineation of CNs vs. CNc, MCIs vs.
MCIc, CN vs. MCI, and CN vs. AD using the ROC curve and the area under the curve
(AUC) for predicted cognitive scores vs. actual values at baseline. The predicted cognitive
tests were learned from all groups in the test set and then the ROC curve along with the
AUC was depicted for the selected groups. The AUC of 0.79 and 0.76 are achieved for
MCIs vs. MCIc groups using the predicted MMSE and ADAS, respectively. The AUC
of 0.69 and 0.72 are achieved for CNs vs. CNc groups using the predicted MMSE and
ADAS, respectively. In addition, the AUC of 0.74 and 0.77 are achieved for MCIs vs.
MCIc groups as well as AUC of 0.69 and 0.73 for CNs vs. CNc groups using the predicted
RAVLT-Im and RAVLT-PF, respectively. The high AUC of estimated cognitive scores for
these groups indicates the power of these tests to predict the conversion in the early stage.

It can be seen that the AUC for the predicted cognitive scores is slightly higher in
comparison to the AUC of actual values especially for the CNs vs. CNc groups for all
considered cognitive tests. These results indicate that estimated cognitive scores based on
structural and functional alternations of the brain contain valuable information for early
diagnosis of the disease which is different from the actual information. In order to test
this hypothesis, an SVM classifier with 10-fold cross-validation was used to classify the
CNs from CNc using the actual cognitive scores and combined of estimated and actual
values. We achieved an average accuracy of 0.63, 0.70, 0.69, and 0.63 for MMSE, ADAS,
RAVLT-Im, and RAVLT-PF, respectively using the actual values and the average accuracy
of 0.69, 0.73, 0.70, and 0.71 using the combined scores which are found to be statistically
significant with the null hypothesis of P-value ≤ 0.05. These results may suggest that the
actual cognitive test scores and predicted scores based on neuroimaging contain different
information which may help for early detection of AD.
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Figure 5.6: ROC curves and AUC values of group classification of CNs vs. CNc, MCIs
vs. MCIc, CN vs. MCI (includes both groups of stables and converters), and CN vs. AD
for cognitive scores of MMSE and ADAS.
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Figure 5.7: ROC curves and AUC values of group classification of CNs vs. CNc, MCIs
vs. MCIc, CN vs. MCI (includes both groups of stables and converters), and CN vs. AD
for cognitive scores of RAVLT-Im and RAVL-PF.
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Figure 5.8 shows the bar plot of predicted cognitive scores for a different combination
of modalities. As can be seen, the RMSE is lower using only MRI modality for prediction
of neuropsychological test scores in comparison to PET and CSF separately, and using
multimodal neuroimaging leads to lower RMSE for all 4 cognitive tests at most of the
time points. When the modalities considered (MRI, PET, CSF) are used separately, it is
observed that MRI has a consistently lower RMSE in predicting cognitive scores. Evidently, the RMSE decreases when using multimodality in comparison to a single modality
for predicting the cognitive scores. For almost all cases and for most time points, the
more modalities or measures are combined (MRI, PET, CSF, APOE), the lower is the
RMSE. However, we investigated the statistical analysis of these results using ANOVA
test to check the statistical difference of RMSE and R2 . The P-values of 0.0000, 0.2310,
0.0006, 0.0819, 0.1433, and 0.0002 for the prediction of MMSE and P-values of 0.0004,
0.0001, 0.0005, 0.0089, 0.0050, and 0.2123 for the prediction of ADAS were obtained
using the single modality of MRI versus multimodal neuroimaging for the 6 time points,
respectively which showed that the proposed method statistically performed best in predicting MMSE and ADAS scores only at some time points although a higher correlation
and lower RMSE were achieved at all 6 time points. The same results also were observed
for RAVLT-Im and RAVLT-PF prediction results. A large amount of missing data may
explain this outcome since we have unbalanced observations for MRI versus PET and CSF
at those time points.

The results of the proposed Gaussian-kernel-based model compared to some other
regression models such as lasso, ridge, fused group lasso (FGL), temporal group lasso
(TGL), and convex fused sparse group lasso regression are listed in Table 5.6. For a fair
comparison, the same train and test data sets have been used for all methods.
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Figure 5.8: Bar plot of RMSE for different combination of modalities at different time
points in 4-year time window for the cognitive tests of (a) MMSE, (b) ADAS, (c) RAVLTIm, and (d) RAVLT-PF.

It should be mentioned that the hyperparameters of all methods were optimized in
each trial with10-time repetition using 5 fold cross-validation. Therefore, only results
of MRI modality for predicting MMSE and ADAS are compared to exemplify this comparison while adhering to space constraints of this study, which we would exceed if we
were to include all other modalities and for all cognitive scores. The statistical analysis
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Table 5.6: Results of our proposed method compared to lasso, ridge, temporal group lasso
(TGL), fused group lasso (FGL), and convex fused sparse group lasso (cFSGL) in terms
of averaged RMSE (standard deviation) using MRI data to predict MMSE and ADAS.
Superscript symbol of ∗ indicates that the marked method significantly outperformed the
others at that time point
MMSE
Ridge
Lasso
TGL
FGL
cSFGL
Proposed
ADAS
Ridge
Lasso
TGL
FGL
cSFGL
Proposed

T1
3.18(0.39)
2.35(0.24)
2.34(0.27)
3.32(3.28)
2.41(0.21)
1.89(0.17)∗
T1
8.11(0.72)
7.20(0.61)
6.98(0.64)
10.19(2.3)
6.48(0.57)∗
6.91(0.61)

T6
2.67(0.26)
2.37(0.21)
2.04(0.26)∗
5.27(0.40)
2.27(0.21)
2.24(0.22)
T6
9.86(0.98)
8.64(0.13)
7.83(0.24)
12.79(3.01)
7.39(0.92)
7.04(0.88)

T12
3.05(0.45)
2.76(0.55)
2.72(0.54)
4.21(0.41)
2.75(0.44)
2.03(0.25)∗
T12
9.56(0.81)
8.23(0.81)
7.86(0.19)
11.70(4.30)
8.35(0.78)
7.60(0.69)∗

T24
3.23(0.39)
2.95(0.35)
3.00(0.41)
3.45(0.51)
3.20(0.65)
1.95(0.29)∗
T24
10.97(1.21)
9.95(0.95)
8.51(0.26)
9.27(2.01)
7.61(0.88)
6.66(0.81)∗

T36
3.23(0.44)
2.85(0.38)
3.02(0.36)
2.82(0.38)
2.87(0.65)
2.09(0.32)∗
T36
12.87(1.86)
8.89(1.30)
6.85(0.88)∗
10.32(2.12)
7.95(1.21)
7.15(1.08)

T48
4.27(0.21)
4.00(0.30)
3.99(0.43)
7.58(0.89)
2.56(0.55)
2.35(0.65)
T48
13.27(2.65)
9.83(1.90)
9.85(0.98)
11.42(3.90)
7.35(2.30)
6.87(1.85)∗

is performed using the Analysis of variance (ANOVA) test to investigate the significant
difference (P-value ≤0.05) of results at each time point in terms of RMSE which are indicated in Table 5.6. This table shows that our proposed method significantly outperforms
the other well-established methods of lasso, ridge, and FGL for all time points and TGL
and cFSGL at most of the time points for predicting MMSE and ADAS.

5.4

Discussion

In this study, the prediction of 4 important cognitive scores have been evaluated using
multimodal neuroimaging with the focus placed on identifying CN and MCI individuals
who later converted to MCI or to AD. We considered 5 groups of converter/stable normal
cognition/mild cognitive impairment and AD with a time window of 4 years including 6
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time points. A 10-fold cross-validation was used to prevent any bias in the training and
testing sets and an ensemble approach was applied to the primary predictions of separatemodality regressions to improve the overall estimation of prediction. We proposed a
kernel-based model to capture the nonlinear associations between the separate modalities
of neuroimaging and neuropsychological test scores.

We investigated the most relevant MRI features that have the highest weights in the
training phase to predict the cognitive scores. We found that white matter volume of left
hippocampus/ left inferior parietal/ right inferior lateral ventricle, cortical thickness average of left middle temporal/ right entorhinal/ right inferior parietal/ left temporal pole, the
cortical volume of right pars opercularis/ left insula, and surface area of left supramarginal
are among the stable features to predict MMSE, ADAS, and RAVLT tests. These observations agree with previous studies in the pathological pathway of Alzheimer’s disease,
which show that the medial temporal lobe, including the entorhinal and hippocampus cortices, is the first to be affected by disease progression [105, 138, 139]. Moreover, bilateral
hippocampal and parahippocampal regions are found among the most important features
in gauging disease progression [100, 140] as well as thickness average and volume of
inferior parietal [105,141]. Moradi et al. found the medial temporal lobe and amygdala as
the top predictors to estimate RAVL-Im and hippocampus, angular gyrus, and amygdala
as the top predictors for RAVLT-PF [128]. The medial temporal lobe especially the hippocampus plays an important role in episodic memory specifically for the establishment
and keeping the memories before storing them to other areas [142, 143].

Although these findings agree with other investigations to find those stable features in
disease progression, the large effect of MCI or Alzheimer’s pathology may overshadow the
cognitively normal group. Since all subjects are considered as a pool, the weight of stable
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features is more significant when subjects already progressed to MCI and AD. Therefore,
we studied the most relevant features in detecting CNs vs. CNc groups. We observed
that cortical thickness average of right precuneus/ left inferior temporal/left insula, white
matter volume of right choroid plexus/right thalamus/left ventral DC, the surface area of
left rostral anterior cingulate/ right superior parietal/ left lateral orbitofrontal/ right pars
triangularis/ left parahippocampal and cortical volume of right rostral middle frontal are
among the most important features. Previous studies found structural changes in right precuneus, superior frontal, and left thalamus [144] as well as the hippocampus, entorhinal
cortex, and ventricles [145, 146] as the most important MRI features for conversion from
CN to MCI which are in line with our observations. We also observed that transition from
CN to MCI or AD is more associated with parietal lobe and prefrontal cortex baseline
atrophy [147–150]. Recent studies also suggest that the insular cortex which is associated
with taste and non-taste recognition memory by interaction with the amygdala as part of
the default mode network was discovered to be disrupted in AD [151, 152]. Our results
demonstrate that in addition to the amygdala and well-known hippocampus, insula, and
middle temporal are also related to verbal episodic memory as reflected in the prediction
of the RVALT scores.

Previous works studied the predictive models for different neuroimaging techniques
in Alzheimer’s trajectory. Stonning et al. applied relevance vector regression on 586 subjects using MRI and CSF modalities and achieved RMSE/R2 of 2.19/0.57 and 7.27/0.59
for prediction of MMSE and ADAS at baseline, respectively as well as 18.97/0.19 for
predicting RAVLT-PF [153]. Zhang and Shen obtained R2 of 0.51 for the prediction of
MMSE and 0.53 for ADAS changes in a 2-year study with a total number of 186 subjects
and using a multimodal multitask approach including the MRI, PET, and CSF [79]. Zhang
et al. achieved RMSE of 2.61 and 2.52 with a correlation of 0.73 for prediction of MMSE

79

as well as RMSE of 5.18 and 5.27 with the correlation of 0.77 for prediction of ADAS
at month 12 and 48, respectively [63]. Moradi et al. used elastic net linear regression
for predicting the two tasks of RAVLT-Im and RAVLT-PF from MRI measurements and
obtained normalized RMSE (nRMSE) of 0.87 along with correlation of 0.5 and nRMSE
of 0.9 along with a correlation of 0.43 for the prediction of RAVLT-Im and RAVLT-PF
scores, respectively [128]. Jie et al. used a temporally-constrained group sparse lasso
using MRI measurements with the time window of 24 months and achieved RMSE/R2
of 2.84/0.65 for predicting MMSE and 5.85/0.67 for predicting ADAS [89]. Liu et al.
proposed a multitask sparse group lasso learning and obtained RMSE/R2 of 2.16/0.52 and
6.59/0.66 for predicting MMSE and ADAS, respectively using the baseline MRI [154]. In
another study the correlation of 0.66 and 0.7 using 𝑙2,1 , 𝑙1 regularized multitask regression
applied on longitudinal data (3-year time window) of MRI, PET, APOE, age, and education were obtained for MMSE and ADAS, respectively [92].

It is worth noting that most of the aforementioned studies excluded the CNc subjects
in their dataset, while we included the CNc group in order to identify individuals at risk
for progressing into MCI or AD. There are few studies focusing on normal cognition
conversion. Some studies investigated the conversion from CN to MCI and AD to test
for the inflection points before the diagnosis of AD [155], to investigate the probable
presymptomatic markers in healthy aging [156], and to estimate if the age of symptom
onset could be similar across generation in subjects with Alzheimer’s history in at least
one parent [157]. Zhan et al. considered a training set of 120 CN and 121 AD subjects,
as well as a test set of 20 CNs and 20 CNc subjects citezhan2015identification. They
achieved 70% accuracy for classification of CNs vs. CNc using multimodal neuroimaging
of MRI, FDG-PET, and AV45-PET in the follow-up for 24 months.
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CHAPTER 6
CONCLUSION
This study aimed to develop several machine learning algorithms to diagnose the
Alzheimer’s disease in its early stage, preferably in its presymptomatic phase where no
manifestation of cognitive decline is yet apparent. To fulfill this aim, two types of crosssectional and longitudinal data analyses have been performed for classifying the different
subject groups as well as for predicting their future cognitive status using the most common cognitive tests.

In the second chapter, a machine learning approach based on a deep neural network
has been proposed for binary and multiclass classifications with a focus placed on the
delineation of EMCI group from the CN controls. The proposed approach introduces the
use of the Adam algorithm to update the learning weights which improves the accuracy of
diagnosis while efficiently updating the learning weights and decrease the time of convergence. We combined multimodal imaging of MRI and PET with the neuropsychological
test scores through the well-known RAVLT, MoCA, and ECogT tests. The high accuracy
of 84.0% for delineating the EMCI group from the CN group and accuracy of 96.8%
for CN and AD classification were achieved. In addition, the proposed deep learning
algorithm is successfully used for multiclass of CN, EMCI, LMCI, and AD classification
as well. During the feature selection and training processes, we found that RAVLT and
ECogT are useful neuropsychological tools for the early detection of Alzheimer’s disease.

In the third chapter, an SVM-based approach with the RBF kernel has been proposed
for binary classification with a focus placed on the delineation of the EMCI group from the
cognitively normal group. Diagnosis of this early prodromal stage of AD could result in
the planning of early treatment and therapeutic interventions to slow down the progression
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of the disease. We combined multimodal imaging of MRI and PET with the neuropsychological test scores through the well-known RAVLT, MoCA, and ECogT tests. The high
accuracy of 81.1% for delineating the EMCI group from the CN group and accuracy of
96.2% for CN and AD classification were achieved. In addition, the accuracy of 75.6%
for CN and EMCI classification has been obtained using only MRI, amyloid PET, age,
and education without using neuropsychological test scores which is higher than all of the
results obtained from previous studies.

In chapter four, a probabilistic approach for finding the most important features augmented with a Gaussian-based model is designed to address the challenging classification
of the EMCI group from the CN group. This approach evaluated the merits of using
the Gaussian process and integrating the Bayesian prediction and classification model as
another direction for the application of machine learning in AD. To this end, we have used
a feature selection method based on the random forest algorithm and applied a recursive
feature elimination (RF-RFE) approach. Many of the related studies involve the MCI
group as a whole in their classification without distinction of the early and late stages of
MCI (EMCI and LMCI), which takes away the ability to detect the earliest signs of AD,
a challenge which this study has aimed to resolve. In addition, a large number of subjects
was considered, proving the ability of the proposed method to be generalized for other
classification purposes.

In chapter five, we introduced a multitask framework to model the disease progression
on a longitudinal data considering the structured sparsity of features with both coupling
across tasks and group selection for individual tasks. This framework is optimized by
the ADMM algorithm to solve for the non-smooth objective formulation. The proposed
framework includes a kernel-based approach to capture the nonlinear relationship between
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neuroimaging data and the cognitive scores along with a decision-tree ensemble to fuse the
separate modalities seeking a strong prediction performance. Our proposed method provides a unified approach to fuse heterogeneous data that cannot be directly concatenated
due to temporal sparsity of modalities as well as allowing for more flexibility in having
different weights for different modalities by specific-regression training. One advantage of
this study relates to the indication of at risk groups of normal cognition and mild cognitive
impairment to delay the onset of symptoms at clinical trials.

In addition, the most important biomarkers can be identified due to the sparsityinducing nature of the algorithm. Four cognitive scores of MMSE, ADAS, RAVLT-Im,
and RAVLT-PF were considered for predictive purposes using the proposed multimodal
neuroimaging platform. The episodic tests as used in this study were shown to be effective for selecting the at-risk groups. We observed that MRI morphometry was the most
sensitive biomarker to predict the conversion and we realized that parietal and prefrontal
cortices are also associated with episodic memory in addition to the temporal lobe. Although adding FDG-PET, CSF, and APOE allele improved the prediction error at all 6
time points and significantly at 4 time points, we observed that using multimodal neuroimaging does not statistically enhance the prediction performance at some time points
due to the large size of missing data. It is clear that for longitudinal studies of this type
(4-year duration), the missing data challenge remains the most difficult to overcome for the
development of any future machine learning algorithm for predicting disease progression.

Limitations
Given the many accomplishments made through this research endeavor, there are still
some limitations to this study that need to be overcome. First, there are obviously other
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biomarkers such as functional magnetic resonance imaging (fMRI) and diffusion tensor
imaging (DTI) that may potentially augment and improve these current classification
and prediction results, especially in terms of the CN vs. EMCI classification and CN
conversion groups. In addition, the presence of noise has not been tested in our study
since the MRI and PET images considered underwent a high level of quality control. It
is essential for any study involving the acquisition of any imaging modality to undergo
quality control to ensure that no shading or aliasing is experienced and that such images
are free from the presence of impulse noise, Gaussian noise, and any other source of noise
that could affect the results of segmentation and the eventual extraction of key structural
or functional features. Moreover, in chapter 4 since finding the optimal threshold for
the Pearson’s correlation using optimization algorithms is time-consuming, we set the
threshold manually in this study. However, we contemplate to investigate using the mean
(𝜇), standard deviation (𝜎) and the upper percentile (𝑧) to determine a practical threshold
of what we assume will be normal distributions of the data under study as 𝑇 = 𝜇 + 𝑧𝜎,
a formula we discovered to work well with electroencephalography (EEG) data in epilepsy.

Furthermore, in chapter five, although 𝛽-amyloid of CSF correlates with the amyloid
level of PET neuroimaging, the two are not identical. Therefore, using the amyloid level
measured by PET as well as the CSF p-tau level using tau imaging instead of CSF may
change the results. In addition, the age-correction procedure could improve the learning
process to predict the cognitive scores, which was not added in our model. Also, one
challenge in clinical data processing is missing values. Although we handled the problem
of missing data using a decision tree-based model to fuse the separate modalities, still the
observations that had missing values in the target were excluded in this study.
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Therefore, these limitations will guide the development of new machine learning
algorithms that would improve these results and to do multiclass classification using a
more comprehensive multimodal neuroimaging platform. In addition, using unsupervised
approaches could exploit the information of unlabeled data for classifying and predicting
conversions in the presence of missing data.
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